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ABSTRACT
MECHANISTIC STUDIES TO UNDERSTAND THE ROLE OF HUMAN GUT
MICROBIOTA IN COLONIZATION RESISTANCE AND GUT HEALTH
SUDEEP GHIMIRE
2020
Human gut microbiota is comprised of thousands of species which fall into two major
categories or “enterotypes” based on dominating bacteria: “Bacteroides” and “Prevotella”.
Bacteroides enterotype dominates the microbiota of the western population because of a
high protein and fat diet, whereas Prevotella enterotype is dominate in the gut of the eastern
population because of a high carbohydrate diet. While most of the microbiota studies
focused on the Bacteroides enterotype using both metagenomics and culturomics,
Prevotella enterotype is understudied, especially in the field of culturomics. The structure
of the Prevotella dominated gut microbiome is revealed by metagenomic studies, but the
individual bacterial species and their characteristics require culturomics and phenotypic
characterization studies. To understand how microbes assemble into communities and
provide colonization resistance against pathogens, we used the culturomics approach to
capture the bacterial diversity of the Prevotella dominated community. We cultured 1590
isolates belonging to 102 bacterial species and characterized them for their substrate
utilization, short chain fatty acid production and inhibition of Clostridium difficile. We
found that 66 bacterial species were able to inhibit C. difficile in vitro. Furthermore, using
a combinatorial community assembly approach, we identified the minimum number of
bacteria required to resist C. difficile in vitro is twelve. During this culturomics, we also
isolated two novel bacterial species from the Prevotella dominated microbiome.
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Furthermore, to understand how the Prevotella dominated community is shaped by certain
prebiotic substrates, we combined rice bran and quercetin to analyze their effect on
microbiome composition in minibioreactors. The combination of these prebiotics
significantly reduces potential pathogenic bacteria by alleviating propionate levels. Also,
there are studies suggesting inhibition of C. difficile may occur by conversion of bile acids
by C. scindens. We analyzed the genetic differences of five C. scindens strains and tested
their ability to inhibit C. difficile in vitro. We found a variation in C. scindens genomes and
their ability to inhibit C. difficile in the presence and absence of bile. This research
improves our understanding of gut microbiota using culturomics and identifies
mechanisms utilized by gut microbes to inhibit C. difficile in vitro, which is valuable step
in the development of biotherapeutics for gut diseases in future.

Key words: Human gut microbiome, culturomics, colonization resistance, minibioreactor,
Clostridium difficile
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CHAPTER 1: IDENTIFYING CLOSTRIDIOIDES DIFFICILE-INHIBITING GUT
COMMENSALS USING CULTUROMICS, PHENOTYPING, AND
COMBINATORIAL COMMUNITY ASSEMBLY
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Abstract
A major function of the gut microbiota is to provide colonization resistance, wherein
pathogens are inhibited or suppressed below infectious level. However, the fraction of gut
microbiota required for colonization resistance remains unclear. We used culturomics to
isolate a gut microbiota culture collection comprising 1590 isolates belonging to 102
species. Estimated by metagenomic sequencing of fecal samples used for culture, this
culture collection represents 34.57% of taxonomic diversity and 70% functional capacity.
Using whole genome sequencing we characterized species representatives from this
collection, and predicted their phenotypic traits, further characterizing isolates by defining
nutrient utilization profile and short chain fatty acid (SCFA) production. When screened
using a co-culture assay, 66 species in our culture collection inhibited C. difficile. Several
phenotypes, particularly, growth rate, production of SCFAs, and the utilization of mannitol,
sorbitol or succinate correlated with C. difficile inhibition. We used a combinatorial
community assembly approach to formulate defined bacterial mixes inhibitory to C.
difficile. When 256 combinations were tested, we found both species composition and
blend size to be important in inhibition. Our results show that the interaction of bacteria
with each other in a mix and with other members of gut commensals must be investigated
for designing defined bacterial mixes for inhibiting C. difficile in vivo.
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Importance
Antibiotic treatment causes instability of gut microbiota and the loss of colonization
resistance, allowing pathogens such as C. difficile to colonize, causing recurrent infection
and mortality. Although fecal microbiome transplantation has shown to be an effective
treatment for C. difficile infection (CDI), a more desirable approach would be the use of a
defined mix of inhibitory gut bacteria. C. difficile-inhibiting species and bacterial
combinations we identify herein improve our understanding of the ecological interactions
controlling colonization resistance against C. difficile and could aid the design of defined
bacteriotherapy as a non-antibiotic alternative against CDI.
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Introduction
Normal functioning of the human gut requires a balanced interaction between our mucosal
surface, diet, the microbiota, and its metabolic by-products. A major determinant of the gut
homeostasis is the presence of a healthy, diverse commensal microbiota which prevents
pathogenic bacteria from colonizing the gut or keeping their number below pathogenic
levels. This function of the gut microbiome is called colonization resistance (1, 2).
Perturbations of the gut microbiome referred to as dysbiosis could result in the loss of
colonization resistance (3). Dysbiosis and loss of gut microbiome colonization resistance
caused by antibiotics, for example, can predispose people to enteric infections.
Clostridioides difficile infection (CDI) of the gut following antibiotic treatment is a clear
demonstration of this phenomenon. Clostridioides difficile is a Gram-positive, spore
forming anaerobe and is the leading cause of antibiotic induced diarrhea in hospitalized
patients (4).

Antibiotic treatment of CDI often causes recurrence (5). It has been shown that infusion of
fecal microbiome from healthy people into CDI patients gut can resolve CDI and prevent
recurrence (6, 7). This procedure termed as fecal microbiome transplantation (FMT) has
become a common treatment for CDI (8). However, there has been concerns regarding the
long-term health consequence of FMT. Recently, there has been reports of weight gain (9)
and mortality due to transfer of multi-drug resistant organisms following FMT (10).
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The development of defined bacterial mixes from the healthy microbiota, which can
resolve CDI, poses an alternative to FMT (11). However, the exact number of species
needed in an efficacious defined bacterial mix for CDI remains unknown, and was
reportedly in the range of 10–33 species when defined bacteriotherapy was tested in a
limited number of patients (12, 13). A mix of spore-forming species tested in phase II
clinical trials, despite its initial success, resulted later in recurrence (14). The use of highthroughput anaerobic gut bacterial culturing, coupled with sequencing, improves the
cultivability of the gut microbiota (15-17), facilitating the development of culture
collections of gut commensals that can be screened for identification of species conferring
colonization resistance, or an understanding of the ecological interactions stabilizing or
destabilizing colonization resistance.

Here we report the cultivation, using culturomics, of 1590 gut commensals comprising 102
species from healthy human donors. We phenotyped and sequenced genomes of the
representative species in this culture collection. We then screened the strains to identify
species inhibiting C. difficile. A combinatorial community assembly approach in which
256 strain combinations were tested to identify the species interactions that improve or
diminish C. difficile inhibition. Our results show that both species composition and
interactions are both important determinants of C. difficile inhibition phenotype.

Our

approach and culture library—besides advancing the understanding of bacterial
community interactions determining colonization resistance—could prove useful in other
studies probing the role of gut microbiota in host health.
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Materials and Methods
Fecal sample collection, culture conditions, isolate identification, and genome
sequencing: We collected fecal samples with the approval of the Institutional Review
Board (IRB), South Dakota State University. All procedures were performed following
IRB guidelines. We collected fresh fecal samples from six healthy adult donors from
Brookings, South Dakota, USA with no antibiotic consumption during the previous year.
We transferred fecal samples to an anaerobic chamber within 10 minutes of voiding and
diluted them 10-fold with phosphate-buffered saline, and mixed individual fecal samples
in equal ratio to make the pooled sample for culturing. We used a modified brain heart
infusion (mBHI) broth (ingredients listed in Supplementary Text 1) for culture. We used
chloroform and heat treatment to isolate spore-forming species. We plated the 104 dilution
of the pooled sample on each of the media conditions described (See supplementary text
1) in strictly anaerobic conditions. We selected 1590 isolates from all culture conditions
and identified them using MALDI-ToF (MALDI Biotyper, Bruker Inc) against reference
spectra (Supplementary Table 1). We identified isolates unidentified at this step using 16S
rRNA gene sequencing, for which we prepared total genomic DNA using the OMEGA
E.Z.N.A genomic DNA isolation kit (Omega Bio-tek, GA) according to the manufacturer’s
protocol. We amplified full length bacterial 16s rDNA using the universal forward (27F)
and reverse (1492R) primers, respectively, under standard PCR conditions. We sequenced
the amplified DNA using the Sanger dideoxy method. We trimmed raw sequences
generated for low-quality regions from either end and constructed consensus sequences
from multiple primers using Genious (18) with default parameters. Based on full length
16S rRNA gene sequence similarities, we determined the phylogenetic relationships of the

7
isolates. For bacteria initially identified using MALDI-TOF, we extracted full length 16s
RNA

gene

sequences

from

the

genome

using

Barrnap

(https://github.com/tseemann/barrnap) for phylogenetic tree creation. The sequences were
aligned using MUSCLE (19) and evolutionary distances were computed using JukesCantor method. Finally we created the Neighbor Joining tree with a bootstrap of 1000
replicates using MEGA6 (20).

To further characterize the strain library, we selected representative isolates from each
species for whole genome sequencing, extracting genomic DNA from overnight culture of
the isolates using the OMEGA E.Z.N.A genomic DNA isolation kit (Omega Bio-tek, GA)
according to the manufacturer’s protocol. We prepared sequencing libraries the Nextera
XT kit, sequencing them using Illumina 2x 300 paired-end sequencing chemistry on the
Miseq platform (See Supplementary Text 1). We first filtered the raw reads for quality and
sequencing adaptors with PRINSEQ (21), and then assembled them de novo using
Unicycler (22), performing quality check of the assembly results with QUAST (23) and
Bandage (24) all in default mode. We performed gene calling using Prokka (25) with a
minimum ORF length of 100 bp.

Characterization of donor fecal samples using shotgun metagenome sequencing: We
extracted total community DNA from 0.25 g of each donor fecal sample using MoBio
Powersoil DNA isolation kit according to the manufacturer’s instructions. To enrich
microbial DNA, using previously published protocol, we depleted host DNA in the isolated
total DNA before sequencing (26). We prepared the sequencing library from 0.3 ng of the
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enriched DNA using the Nextera XT library preparation kit (Illumina inc. San Diego, CA),
performing sequencing following the protocols used for bacterial genomes described
above. After quality correction, we removed human host reads using Bowtie2 v.1.1.2(27)
and performed taxonomy assignment using Kaiju (28) in greedy mode. We searched reads
against the proGenomes (29) reference database of protein sequences containing a nonredundant set from more than 25,000 genomes from every species cluster recovered by
specI (30), using the NCBI non-redundant database for comparative analysis. Thereafter,
we calculated the Simpson dominance index (D), Shannon Diversity Index (H) and
Shannon Equitability Index (EH), using an assembly-based approach to characterize the
donor fecal metagenomes. For this, we assembled reads de novo using default metaSPAdes
(SPAdes 3.12.0) (31), specifically designed for assembly of complex metagenomic
communities. For initial assembly, we error corrected reads using spades-hammer with
default parameters, thereafter checking assembly results with default MetaQUAST v 5.0
(32). We removed contigs of less than 500 bp from the resultant datasets, and performed
ORF predictions on the filtered contigs with MetaGeneMark (33) with a minimum length
cutoff of 100 bp.

Computation of gene repertoire and the functional analysis of isolate genomes and
donor fecal metagenomes: To determine the gene repertoire in the isolate genomes and
donor fecal metagenomes, we constructed a non-redundant gene catalog from our total data
using cd-hit (34, 35) for comparison against the previously published integrated catalog of
reference genes in the human gut microbiome (36). After gene calling, we clustered the
concatenated datasets from the culture library using cd-hit at >95% identity with 90%
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overlap. We checked these datasets using BLAT to avoid over-representation in the gene
catalog. We then compared our gene dataset against the previously mentioned integrated
catalog (36). For functional mapping, we mapped amino acid sequences from all the
individual datasets and clustered non-redundant sets against the EggNOG database v3.0
(37).

For gaining a better insight into the putative and hypothetical population genomes present
within the donor fecal samples, but not isolated using the culturomics approach, population
genome bin creation is considered superior to taxonomy assignment of the raw reads. We
therefore constructed population genome bins from the metagenomes using MaxBin2with
acceptance criteria of 90% completeness and < 5% redundancy, mapping back raw reads
on the assembled contigs using Bowtie2 (38) for coverage information. We further
analyzed all high-confidence bins with specI (30) for species cluster determination. To
determine the abundance of isolated species from the pooled donor fecal samples, we
measured the coverage by read mapping with Bowtie2 (38) at 95% identity level. For the
functional analysis, we performed KEGG annotation for the ORFs obtained from the
pooled donor fecal metagenome and the isolate genomes. We searched data from all
comparisons for KO modules using GhostKOALA (39), and performed hierarchical
clustering of the datasets to generate heat maps with R (http://www.R-project.org/). We
used Traitar (40) under default parameters to predict 67 phenotypes from the whole
genomes of all species in the culture collection.

10
Phenotypic characterization of the isolated strains: To correlate the genomic features
with phenotypes, we further characterized the strains for which genomes were sequenced
by determining the following phenotypic properties:

Carbon source utilization: We determined the ability to utilize 95 carbon sources using
Biolog Biolog AN MicroPlateTM. Briefly, we grew strains on mBHI plates anaerobically
for 24 h–48 h at 370C. We used a sterile cotton swab to scrape cells from the plates and
suspended them in AN inoculating fluid (OD650 < 0.02), using 100 µl of this suspension to
inoculate AN MicroPlateTM in duplicate, and incubated them at 370C anaerobically. We
took OD650 readings at 0 h and 48 h post-inoculation and normalized the results for growth
against water and 0-h OD650 values.

Production of SCFA: To analyze the SCFAs produced by isolates, we grew strains in mBHI
for 24 hours in anaerobic conditions and added 800 µl of the bacterial culture to 160 µl of
freshly prepared 25% (w/v) m- phosphoric acid, and froze them at −800C. We thawed
samples and centrifuged them (>20,000×g) for 30 min. We used 600 µl supernatant for
injection into the TRACE1310 GC system (ThermoScientific, USA) for SCFA analysis.

Identification of C. difficile-inhibiting strains: We used a co-culture assay in which
pathogen and test strains were cultured together at a ratio of 1:9 to identify C. difficileinhibiting strains in our library, using only those strains reaching OD600 of 1.5 after 24 h
of growth in mBHI; 82 species met this criterion. We used C. difficile strain R20291 as the
reference strain in the first assay. Briefly, we grew all test strains and C. difficile R20291
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in mBHI medium anaerobically at 370C and adjusted the OD600 to 0.5. The pathogen and
the test were mixed together at a ratio of 9:1 and incubated for 18 hours anaerobically at
370C. We then plated 10−5 & 10−6 dilutions onto C. difficile selective agar, using
monoculture of C. difficile R20291 as a positive control. We compared colony forming
units (CFUs) enumerated from co-culture plates against the C. difficile R20291 control. In
identifying C. difficile-inhibitors in healthy and CDI patients, we calculated the frequency
of 16 top C. difficile-inhibitors in our collection by metagenome read mapping from a
previously published dataset (41).

Sequence data Availability: All metagenomic datasets from this project has been
deposited in NCBI SRA under the bioproject PRJNA494584. Raw whole genome
sequence data for all the isolates has been deposited under the BioProject PRJNA494608.

Results

Single medium based culturomics retrieves high species diversity from donor fecal
samples: In this study, we used metagenome sequencing to characterize the fecal
microbiome composition of healthy human donors and culturomics to develop a strain
library to identify C. difficile inhibiting species. As a first step, donor’s fecal samples were
characterized using shotgun metagenome sequencing. To this end, fecal samples from six
donors were sequenced individually and also after pooling in equal proportion. We used
high sequencing depth for the metagenome sequencing. Collectively, the datasets from all
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Figure 1: Gut microbiome composition of donor’s fecal samples. A. Variations in the
Simpson Dominance (D), Shannon Diversity (H) and Shannon Equitability (EH) indices
calculated based on the raw reads taxonomic affiliations for individual fecal samples (S1–
S6) and pooled fecal sample (S7). B. Phylum level distribution of bacteria for individual
fecal samples (S1–S6) and pooled fecal sample (S7). We calculated relative abundance
values as compared to the total identifiable reads from any dataset. C. Species-level
distribution of the pooled donor fecal sample (S7). We performed taxonomic classification
using Kaiju. We referred all species with under 1% abundance to “other” category.
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samples constituted 48.9 Gb of data. To determine the diversity of the samples, Simpson
dominance index (D), Shannon diversity index (H) and Shannon equitability index (EH)
were calculated for individual samples as well the pooled material. This statistical analysis
(Hutcheson t-test, p > 0.1) revealed that all donor samples were similar in diversity indices
and pooling the samples in equal proportion maintained the overall population structure of
the individual samples (Figure 1A). The donors in this study were recent migrants to the
United States from Asia and were expected to have a high proportion of Prevotella
(Prevotella enterotype) in the gut microbiome. Consistent with this expectation, taxonomic
diversity of the samples in phylum level (Figure 1B) showed the dominance of
Bacteriodetes while the most abundant genus was Prevotella (Figure 1C).

Using culturomics, we developed a strain library from the pooled fecal samples. Previous
studies have prevalently used assorted media to isolate gut bacteria (15). For mechanistic
studies to understand the microbial community interaction, strains need to be pooled in a
single nutrient medium. While the approach of using different media conditions is useful
in retrieving high diversity, strains isolated in various media conditions may not be able to
grow in a single media. This would prevent the use of a culture library in community
assembly studied in a universal medium. To avoid this problem, we used a modified Brain
Heart Infusion (mBHI) as the base medium for culturing. We isolated several strains from
nine species from the mBHI medium. We reasoned that if the species that were growing
fast in the mBHI medium is suppressed, additional species diversity could be isolated using
the same medium. We therefore supplemented mBHI with different combinations of
antibiotics selected to suppress the formerly dominant strains, also using heat shock and
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chloroform treatment to select for spore-forming species. We used 12 conditions for
culturing (Supplementary Text 1), selecting 1590 colonies from these conditions. We
determined strain species identity using MALDI-ToF, and 16S rRNA sequencing
(Supplementary Table 1). We thus isolated 93 more species from the same sample,
increasing the total diversity in our strain library to 102 species (Figure 2). In Figure 3A,
we present the frequency of each species isolated in each culture condition. We further
examined whether our approach could isolate high- and low-abundance species from the
sample. We therefore sequenced the genome of one representative isolate from each
species in our library (Supplementary Table 2), mapping the metagenome reads
(Supplementary Table 3) against the individual species genomes. We mapped 37,669,789
reads obtained from the pooled sample to species whole genomes (Figure 3B), matching
19,109,642 reads—34.57% of the total metagenomic diversity—to the metagenomic reads.
Our single medium-based culturomics method was able to isolate about 34.57% of the
pooled culture sample diversity. We mapped about 20% reads against the Prevotella copri
SG-1727 genome isolated from six different conditions—unsurprising, as the fecal donors
belonged to the Prevotella enterotype. However, we isolated low-abundance species such
as Olsenella umbonata, for which only 0.5% reads were mapped, in eight different
conditions (Figure 3B). We isolated both low- and high abundance species with our
technique and used metagenome binning to estimate the number of species missed by our
method. Matching metagenome bins against cultured species genomes, we found 50
matching culture isolates and 33 bins matching none, indicating that our method failed to
cultivate those metagenome bins (Supplementary Table 4).
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Figure 2: Neighbor-Joining tree of the full length 16S rRNA gene sequences of 102
cultured species isolated from the pooled donor fecal sample. We computed the
evolutionary distances using the Jukes-Cantor method, presented in the units of the number
of base substitutions per site in MEGA6. Symbols and colors represent four different
bacterial phyla, as referred to the legend. We have highlighted putative novel species (n =
2) with “green” text.
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Figure

3:

Efficiency

of

species

retrieval in the culture conditions
tested. A. Frequency of isolation of 102
species recovered. B. Prevalence of
individual species as found from read
mapping

against

metagenome.

donor

fecal
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Single medium based culturomics retrieves most frequent gut bacteria in human
populations and increases gene repertoire in the integrated gene catalog of the gut
microbiome: The availability of high-quality metagenome data from many human samples
facilitates the identification of frequently present gut bacterial species in healthy
populations. A recent study defined 71 bacteria present across 2144 human fecal
metagenomes (42). To quantify the number of these present in our culture library, we
matched the whole genomes of 102 bacterial species and 33 metagenome bins against these
71 frequent species (42), finding our culture library contained 65 of these most frequent
bacteria (Supplementary Table 4). To determine the relationship between the gene
repertoire in our culture library and the integrated gene catalog (IGC) of the human
microbiome, we compared the two datasets. For the comparison against IGC, a nonredundant gut microbiome gene set of 9.879 million genes generated using 1,267 human
gut metagenomes from Europe, America and China (36), we generated a non-redundant
gene set from our cultured genomes and the sample metagenome used for culturing. We
created 984,515 open reading frames (ORFs) from sample metagenomes and 285,672
ORFs from cultured species genomes (Supplementary Figure 1A and Supplementary Table
3) and mapped them against the IGC. Of 285,672 ORFs obtained from cultured genomes,
we matched 208,708 ORFs (73.05%) to the IGC, while 572,437 ORFs (58.14%) of 984,515
ORFs obtained from the sample metagenome matched the IGC (Supplementary Figure 1B
and 1C). In other words, the IGC lacked 26.94% of the ORFs from the cultured isolates
and 41.85% of the ORFs from the sample metagenome. This shows the potential for
expansion of the IGC if more Prevotella enterotype donor fecal samples, such as those
used in our study, are sequenced. Our results also show that sequencing cultured species
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Supplementary Figure 1: A. Numbers of open reading frames (ORFs) found in this
study in genomes and metagenomes and its comparison with IGC. A. Numbers of nonredundant ORFs predicted in 102 cultured species and donor fecal metagenomes. We
generated the number of non-redundant ORFs at 95% identity cutoff for donor
metagenomes and 102 isolates. B. Comparison of the non-redundant ORFs generated form
102 cultured species with the existing integrated human gene catalog (IGC). C.
Comparison of the non-redundant ORFs generated from donor metagenomes with the
existing IGC.
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genomes identifies genes otherwise missing in metagenome sequencing because of low
depth or assembly issues.

A large number of species in the culture library inhibits C. difficile in vitro: A healthy
microbiota suppresses pathogen growth in the gut. To identify C. difficile-inhibiting
species in our culture library, we screened it against C. difficile using a co-culture assay.
Slow-growing strains would be outcompeted by C. difficile. We therefore used 82
moderately- or fast-growing species in the co-culture assay. When tested, 66 species
inhibited C. difficile to varying degrees (Figure 4). In this screen, Bifidobacterium
adolescentis strain SG-742 was the most efficient inhibitor. Furthermore, all Bifidobacteria
inhibited C. difficile, signifying their importance in colonization resistance to this
pathogen. The Lachnospiraceae family were major inhibitors. In a surprising result, 16
species in our co-culture assay increased the growth of C. difficile (Figure 4), a finding of
clinical significance, in that a high abundance of these species may confer a higher risk of
CDI.

Most inhibitors are acetate or butyrate producers: Gut bacteria metabolize diverse
substrates to produce short chain fatty acids (SCFAs) in the gut (43, 44). SCFAs—
particularly butyrate—act as gut epithelial immune modulators, energy sources for host
intestinal cells, and pathogen-inhibitors (45, 46). To determine the relationship between
SCFAs produced and C. difficile inhibition, we estimated the SCFAs produced by all
species used in the co-culture assay (Figure 5). Our results show that the strains produce
mainly acetate (Figure 5A, Supplementary Table 5). Comparing all strains at phylum level
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Figure 4: Inhibition of C. difficile by individual species in vitro. C. difficile CFU counts
for every individual co-culture assay performed for 82 test species in triplicate. Error bars
represent standard deviations of the three independent experiments for each inhibition
assay for individual species. “Green,” “yellow” and “gray” bars represent CFU counts of
C. difficile for inhibitors, control C. difficile, and non-inhibitors, respectively in co-culture.
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Figure 5: Short chain fatty acid (SCFA) produced by cultured species. A. SCFA
production by 82 species used for inhibition assay against C. difficile. We measured
acetate, propionate, isobutyrate, butyrate, isovalerate and valerate using gas
chromatography, expressed in mM concentration. The figure represents mean SCFA
measurements from duplicate samples. Color scale bar: “white”: no SCFAs production;
“dark”: ≥5 mM SCFA production. B. acetate, C. butyrate, D. propionate and E. isovalerate
production in three major phyla from 80 bacteria when oriented according to phyla
(Kruskal–Wallis tests, p<0.05). SCFAs levels for two members of Proteobacteria phyla are
not shown in B, C, D, and E.
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using the non-parametric Kruskal–Wallis test, we found Actinobacteria and Bacteroidetes
to yield the most acetate (Figure 5B). Firmicutes produced significantly higher butyrate
than Bacteroidetes (Figure 5C). Other SCFA production did not differ significantly (Figure
5D & 5E). The majority of high acetate- or butyrate producers were C. difficile-inhibitors.

Relationship between nutrient utilization, C. difficile inhibition and species prevalence
in patient populations: Commensal species suppress pathogens in the gut chiefly by
competing for nutrients (47-49). The Biolog AN MicroPlate™ test panel provides a
standardized method to identify the utilization of 95 nutrient sources by anaerobes.
Investigating the relationship between nutrient utilization and pathogen inhibition, we
determined the nutrient utilization of all species in our library. C. difficile is known to
exploit mannitol, sorbitol or succinate to invade and produce infection in the human gut
(50, 51). Consistent with this observation, we found 27 C. difficile-inhibitors that utilized
all three nutrients as carbon sources (Figure 6). We hypothesized that if the C. difficileinhibitors we identified were active in C. difficile suppression in vivo, their abundance
would be reduced in the gut during antibiotic treatment and CDI. Hence, we determined
the abundance of the top 16 (top 25%) C. difficile-inhibitors in our library from a study of
healthy and CDI patient gut microbiomes (41). We determined the frequency of the top 16
C. difficile-inhibiting isolates in the following groups of human gut metagenomes; (a) CDI
patients, (b) antibiotic-exposed but no CDI patients, and (C) no antibiotic exposure and no
CDI (healthy) people. Consistent with our hypothesis, the top 16 C. difficile-inhibitors in
our screen constituted about 20% of total abundance in the heathy microbiome but were in
low-abundance in both antibiotic-treated and CDI patient gut samples (Figure 7A).

23

Figure 6: Utilization of 95 nutrient sources by the cultured species. The heatmap
represents two independent substrate utilization tests normalized against control. Columns
and rows represent nutrients and strains respectively. We considered growth of ≥ 20% in
any substrate as compared to the control as positive. “Blue,” “white” and “red” represent
low, medium and high utilization of the carbon source, respectively. Top row shows
nutrient utilization of C. difficile. All other strains are arranged in descending order of
nutrient utilization similarity when compared to C. difficile. We used nearest neighbor
clustering based on the Pearson correlation to identify nutrient utilization similarity of other
strains when compared to C. difficile.
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Figure 7: Frequency of the top 25% C. difficile inhibitors obtained in this study in the
gut microbiome of C. difficile infected (CDI) and non-CDI patients. AB+ and ABrepresent samples from non-C. difficile infected patients treated with antibiotics and nonC. difficile infected patients without antibiotic treatment, respectively. A. The combined
abundance of top 25% CD-inhibitors (n = 16) from this study in CDI, AB+, and ABmetagenomes. B. Individual abundance of the same 16 strains in CDI, AB+, and ABmetagenomes. We obtained public metagenomes for CDI, AB+, and AB- from Milani et
al., 2016.
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Supplementary Figure 2: Hierarchical
clustering of KEGG modules from fecal
sample metagenome, all the 102 species
(All_isolates), and subsets that were
found to inhibit C. difficile R20291
(CD_inhibitors).

We

annotated

predicted ORFs from the pooled donor
fecal metagenome and consortium of
cultures for KO modules by searching
against the KEGG database using
Ghostkoala.

We

indicate

the

completeness of the KEGG modules by
the color gradient where we refer to a
complete module by “0” and the absence
of a whole module by “4.”
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Interestingly, Prevotella copri (SG-1727)—among the most abundant species in the donor
samples—was among the species depleted during antibiotic treatment and CDI (Figure
7B).

Analysis of genotype–phenotype relationships: To identify other phenotypes not covered
in our phenotype assays and to link phenotype with genotype, we used Traitar (52) to
predict 67 phenotypes from the genomes of all species in our library. The substrate
utilization phenotypes based on the Traitar prediction mostly matched the Biolog
phenotypes (Figure 8A, Supplemental table 6). The first two clusters (green and red, lower
Figure 8A) comprised mostly the pathogen-inhibitors tested here. The defining traits in
these clusters related to sugar hydrolysis, mostly matching the Biolog phenotype data. The
other two clusters (sky blue and mixed) comprised mostly pathogenic species and slow
growers. Notable traits for pathogen clusters were catalase activity, beta hemolysis activity,
growth in glycerol and high osmo-tolerance (Figure 8A). To further differentiate these
traits, we performed principal component analysis (PCA) on the Traitar data. The PCA plot
(Figure 8B) revealed four distinct clusters (C. difficile-inhibitors, -non-inhibitors,
pathogens, and slow-growing strains) that explained 67.1% total variance in the first two
principal components. Slow-growing strains clustered furthest from C. difficileinhibitors—logically for any colonization-resistant bacteria, as a fast growth rate would
more likely outcompete the pathogen.

To understand the genomic basis of colonization-resistant and pathogen-inhibiting strain
genomes, we used KEGG modules—characteristic gene sets that can be linked to specific
metabolic capacities or other phenotypic features of a genome. We identified 515 modules
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Figure 8: Prediction of phenotypes from the genomes of the 102 species in the culture
library. A. Clustering of 102 species based on 67 traits predicted using the Traitar package.
Each column represents one of 67 traits whereas rows represent 102 species from this
study. The color scheme of the columns further depicts 11 phenotypic properties from
proteolysis to enzyme production. B. PCA using the combined predicted traits from Pfam
annotation. X- and Y-axes show Principal Component 1 & 2, explaining 57.5% and 9.6%
of the total variance, respectively. Prediction ellipses are based on 0.95 confidences. Color
scheme in the legends represents four different categories of isolates.
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in the sample metagenome and 476 modules in the strain genomes. 432 modules were
common between our sample metagenome and our strain genomes, demonstrating our
ability to retrieve 77.28% of the metabolic functional capacity of the fecal microbiome
using our culture method. 82 modules unrecovered in our isolated species comprised
pathways related to environmental information processing, several components of cell
signaling, DNA replication and repair pathways, lipid metabolism, RNA and protein
processing, and the ubiquitin system (Supplementary Figure 2). We then tried to identify
differences in KEGG modules associated with pathogen-inhibiting and -non-inhibiting
strain genomes, finding 26 modules present in C. difficile-inhibitors were absent in non-C.
difficile-inhibitors. Some important modules absent in non-inhibiting species genomes
were M00698 (multidrug resistance efflux pump BpeEF-OprC), M00332 (Type III
secretion system), M00438 (Nitrate/nitrite transport system), and M00551 (Benzoate
degradation). Further work is necessary to understand how these functional modules relate
to colonization resistance.

Design of defined mix of C. difficile-inhibitors: While single strain vs pathogen coculture assay is informative in identifying pathogen inhibiting strains, the inhibition
patterns are likely to change when inhibiting species interact as a community. These
communities may express emergent properties difficult to predict from the individual
members (52). After defining the isolate phenotypes, we used a combinatorial assembly of
bacteria from our culture collection to design a tractable mix of C. difficile-inhibiting
isolates. In the first set of experiments, we mixed 15 inhibiting species in equal proportion
and tested them against C. difficile using the co-culture assay used for individual strains.
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Figure 9: C. difficile inhibition efficiency of the consortia A. Combinations starting with
15 species pool B. Combinations starting with 12 species pool C. Combinations starting
with 10 species pool. “Green,” “blue” and “gray” bars represent the parent blend, blend
with one bacterial species removed at a time and blend with two bacterial species removed
at a time, respectively. “Red” line represents C. difficile control growth. We normalized
the growth of C. difficile in each consortium to control C. difficile growth, so as to obtain
relative C. difficile growth (represented as % C. difficile growth) in each consortium
condition. We performed each experiment in triplicate, and error bars represent the
standard error of the mean.

s
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Table 1 describes the overall properties of these isolates, selected based on the criteria of
the medium pH not dropping below 5.6 after 24 h growth, and representation of overall
taxonomic diversity at the family level. Investigating how changes in the mix composition
could affect the inhibition capacity, we removed one or two species at a time from the mix
of 15 species to create additional mixes, thus testing 121 mixes listed in Supplementary
Table 8 against C. difficile in co-culture assay format. As shown in Figure 9, the removal
of strains from the 15-species mix had both positive and negative effects. When we
removed species, several mixes were less effective than the 15-species mix, and the
removal of two species increased the inhibition efficiency in a species dependent manner.
Out of 121 mixes tested, mix number 22, comprising the species listed in Supplementary
Table 7, most effectively inhibited C. difficile growth (by 79.41%). This clearly
demonstrates the dependence of inhibition efficiency on the species composition of the
defined mix used in the co-culture assay. Seeking the minimum number of species
necessary for an effective C. difficile-inhibiting mix, we performed another set of
experiments in which either one or two species at a time were removed from the parent
mix of 12 species. In this round, we tested 79 bacterial mixes comprising species listed in
Supplementary Table 8 in the co-culture assay. As shown in Figure 9, removal of species
mostly reduced inhibition efficiency when compared with the parent blend. Again, the
efficiency was dependent on the species composition of the mix. We performed a third set
of experiments to determine mixes comprising under ten species that would impact C.
difficile inhibition efficiency. Removal of species from the 10-species parent set
diminished inhibition efficiency overall; however, some mixes increased the growth of C.
difficile. Since all the strains we used individually inhibited C. difficile, the enhancement
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of C. difficile growth by these set mixes clearly demonstrates that individual strain
phenotype can be overridden by species community interactions. In this case, a set of C.
difficile-inhibitory species, when mixed in a particular combination, increased C. difficile
growth. Overall, our results demonstrate that new phenotypes masking the individual strain
phenotype could emerge when microbial consortia are formed, and this emergent property
needs to be taken into account while designing defined C. difficile-inhibiting bacterial
mixes.

Discussion
We developed a gut commensal culture collection from healthy human donors and
identified C. difficile-colonization-resistant strains. As human gut microbiome composition
varies across populations, donor selection for culture is an important consideration.
Depending on the proportion of Bacteriodes and Prevotella, the human gut microbiome
has been classified into enterotypes (53). The Asian and African populations—two-thirds
of the human population fall into the Prevotella enterotype. (54). Information about the
colonization-conferring species in Prevotella-dominant gut microbiomes is limited; we
therefore chose recent Asian immigrants in the US as the fecal donors in this study. For
culture, we used a pooled sample from six donors before culturing, which could have
positive and negative consequences. Pooling can save substantial time and resources. For
instance, after pooling we analyzed 1590 colonies; were this to be done individually, the
number of analyzed colonies would have been 9540. Pooling, however, may distort the
microbiome composition of individual samples, creating artificial population assemblages
(55). For gut microbiome ecology studies, a gut commensal culture collection isolated from
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fecal donors of similar gut microbiome composition could be more useful than that from
many different people. The publicly available gut microbiota culture collection from the
human microbiome project is isolated from 265 people (56). Other similar culture
collections are also isolated from at least over 100 donors (15, 17). Although such
collections are useful as reference strains, since the donors may have different microbiome
compositions, the strains isolated may not form stable ecologies if mixed together. In
contrast, our collection, from a limited number of donors having similar microbiome
composition, may form a stable ecology when mixed, and could be more useful for studies
to understand underlying interactions determining colonization resistance and other traits.

Two general approaches have been used previously for developing gut microbiota culture
collections: the use of culturing samples in several—often up to 64—different nutrient
media conditions, to isolate diversity (15, 57, 58); or the use of a single medium, needing
less time and resource but retrieving fewer species (59). In understanding the types of
bacterial communities responsible for suppressing pathogen growth in the gut, the
assemblage of simple to complex bacterial communities from cultured strain libraries and
testing of such consortia against pathogens is commonly performed. Although the use of
different nutrient media is highly efficient in isolating the maximum number of species
from gut samples, strains so isolated may not grow in a common nutrient medium,
diminishing the utility of the strains in community assembly studies. We therefore used a
single medium-based approach using mBHI for culturing of the fecal bacteria. As shown
in Figures 2 and 3, we isolated 102 species—representing about 34.57% species diversity
determined by sequencing the donor fecal sample—by adjusting the mBHI medium
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(Supplementary Figure 1)—comparable to other single medium-based approaches (59-61).
Furthermore, results in Supplementary Table 3 and Supplementary Figure 2 shows that the
34.57% diversity isolated represents over 70% functional capacity of the donor gut
microbiome. According to the insurance hypothesis of microbiota function, more than one
species performing the same function is recruited in an ecosystem to allow for functional
redundancy (62, 63), possibly explaining the recovery of 70% function from 34.57%
species diversity in our library.

Many strains in our culture collection shown in Figures 4 inhibit C. difficile at varying
levels. Several phenotypes—particularly, growth rate, production of SCFAs, and the
utilization of mannitol, sorbitol or succinate—correlated with the C. difficile-inhibitor
phenotype, consistent with previous reports that restoration of depleted SCFAs in the gut
resolved CDI (64, 65) and competition between C. difficile and commensals for nutrients
and increased availability of mannitol, sorbitol or succinate allowed C. difficile invasion of
the gut (50, 51). Top inhibiting species in our collection were also depleted in the CDI
patient gut, indicating their role in providing colonization resistance against C. difficile
(Figure 7). The formation of many different defined bacterial mixes using these inhibitory
strains may improve the inhibition capacity of the individual strains. Overall, we tested 256
defined mixes using the combinatorial community assembly approach. The combinatorial
community assembly method presented in Figure 9 shows two important parameters
defining the efficacy of the defined mixes—the number and type of species in the mix.
Reducing the number of species in the mix from 15 to 12, did not diminish the overall
inhibition capacity, but reducing the number to ten species did so. Furthermore, many of
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those mixes increased, rather than inhibiting, C. difficile growth. Clearly, adding too many
species in a mix does not improve inhibition. The threshold of peak efficacy is 12 species
in the conditions we tested. Our results also underline how, when species are pooled in a
sub-optimal ecology, undesirable traits could emerge; strains in combination could produce
new phenotypes not observed individually. Previous work to identify a defined mix of C.
difficile-inhibiting bacteria also identified varying mix numbers. For instance, more than
20 years ago, Tvede and Rask-Madsen showed that infusion of a 10-bacterial mix into a
patient’s colon could resolve CDI (12). Another study in a small patient population found
treatment with a 33-bacterial mix could alleviate CDI. In a mouse model, Clostridium
scindens was a more efficient C. difficile-inhibitor when mixed with a defined pool of other
commensal bacteria (66). Likewise, a mix of six phylogenetically diverse bacteria
alleviated CDI in a mouse model (67). The complexity of the gut microbiota and its
variations across populations make the design of defined bacterial C. difficile-inhibiting
mix not simply a matter of mixing large numbers of diverse species. Since our results show
that the C. difficile-inhibiting phenotype changes substantially depending on the microbial
interaction, design of a defined bacterial mix requires a deeper understanding of how
inhibiting species interact with themselves and the members of the total commensal
community.

Conclusion
Overall, we demonstrated that a high percentage of the cultivable fraction of gut microbiota
from healthy human donors are C. difficile-inhibitors in vitro. Defined bacterial mixes can
enhance the inhibition capacity of individual strains. However, depending on the ecology
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of the mix, new phenotypes could emerge. For instance, a mix of bacteria, rather than
inhibiting, can increase the growth of C. difficile. In designing defined C. difficileinhibiting bacterial mixes in vivo, the interaction of bacteria with each other in a mix and
with other members of gut commensals demands investigation. The approach of
combinatorial testing of strains with well-defined phenotypes used in the present study is
a step in that direction.
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For Supplementary Text 1 and Supplementary Table 1-7 please refer:
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Abstract
An anaerobic isolate SG772 belonging to the genus Blautia was isolated from healthy
human fecal sample. When compared using 16s rRNA sequence identity, SG772 showed
only 94.46% similarity with its neighbor species B. stercoris. Since strain SG772 showed
both phenotypic and genomic differences with other members of the type species within
the genus Blautia, we propose the designation of SG772 as novel species “Blautia
brookingsii SG772T”.

Keywords: Blautia brookingsii SG772T, culturomics, gut microbiota, taxogenomics
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Introduction
The human gut microbiome of European and North American population is typically
dominated by Bacteroides while Prevotella dominates Asian and African populations(1).
To determine the cultivable microbial diversity of the Prevotella dominant human gut
microbiota, fecal samples were cultured from six healthy donors using a high-throughput
culturomics approach(2). A new species of a bacterium belonging to the genus Blautia was
isolated during this study. We characterized this strain using the recently proposed taxonogenomics strategy which utilizes the combination of phenotypic and genomic
characterization of the strain to define new species. Herein, we describe strain Blautia
brookingsii SG772T (DSM 107275=CCOS 1888) that was isolated from the healthy human
gut microbiota.

Materials and Methods, Results and Discussion

Isolation and growth conditions
The strain was isolated on a Brain Heart Infusion (BHI) agar medium after 48 hours of
incubation at 37oC in strict anaerobic condition (85% nitrogen, 10% carbon-dioxide, 5%
hydrogen). The strain grew in the pH range of 5.5-7.5 with optimum growth at 6.8. No
growth of was observed after 20 min of thermal shock at 80oC suggesting its non-spore
forming nature.

50
Phenotypic characteristics
The colonies grown in agar plates appeared to be round, whitish, convex and smooth after
48 hours of anaerobic incubation on BHI plate. Cells were gram-positive and coccobacillus
in shape with no flagellum suggesting non-motile nature. Overnight culture of the strain
SG772T in the broth was centrifuged at 10,000×g. The supernatant was then removed to
obtain the pellet which was mixed with 30% glycerol solution and frozen to -800C and sent
to BGSU Center for Microscopy (Bowling Green, OH) for scanning electron microscopy.
The size of the bacterium under scanning electron microscopy was between 0.5-0.8 x 1.82.5 µm (Figure. 1).

Using API ZYM strip, enzymatic activities were determined. Positive enzymatic reactions
were observed for esterase (C4), esterase lipase (C8), leucine arylamidase, acid
phosphatase,

-galactosidase,

-galactosidase,

-glucosidase

and

N-acetyl--

glucosaminidase. Carbon source utilization of the strain SG772T was determined using
BIOLOG AN plate. The strain SG772T was grown as lawn in BHI plate for 48 hours and
the cells were scooped using sterile cotton swab to mix in BIOLOG AN fluid until the
OD600 reached 0.01. 100 µl of the mixture was pipetted into 96 wells of the BIOLOG AN
plate and incubated for 24 hours. The initial and final OD were measured and compared to
control. Those wells with OD growth >20% compared to control were considered as
growth. Thus, this test revealed that the strain utilized 21 substrates with maximum
preference for propionic acid followed by L-alanyl-L-glutamine (Table 1). Furthermore, it
was able to utilize complex carbohydrates like palatinose, rhamnose, arbutin along with
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Figure 1: Scanning electron micrograph of Blautia brookingsii SG772T sp. nov.
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Figure 2: Phylogenetic tree highlighting the position of strain SG772T with regard to
other closely related species. The consensus phylogenetic tree showing the was
constructed using 16S rRNA gene sequences from strain SG772T and its top 30 neighbors
obtained from EzTaxon. The evolutionary history was inferred using Neighbor-Joining
method using Kimura 2-paramter method. The numbers at the nodes indicate bootstrap
values expressed as percentages of 1000 replications in MEGA X. Clostridium butyricum
DSM10702 was taken as an outgroup. GenBank accession numbers are shown in
parentheses.
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organic acids such as -ketovaleric acid, urocanic acid, glycoxylic acid, fumaric acid,
galacturonic acid and -hydroxybutyric acid. Comparison of the substrate utilization of
strain SG772T with other neighbor Blautia strains are given in Table 1. Additionally,
cellular morphology and optimum pH for growth varied among the different species (Table
1). Antibiotic sensitivity test using disk diffusion technique displayed that the strain
SG772T was resistant to tetracycline and streptomycin. However, it was susceptible to
chloramphenicol, ampicillin, erythromycin, and novobiocin.

Strain Identification
After initial isolation of the strain SG772T, MALDI-TOF was performed resulting no
identification (score < 1.7). Therefore, DNA of the strain was isolated and 16S rRNA gene
was amplified and sequenced using Applied Biosystems 3500xL, Genetic analyser
(Applied Biosystems, MA, USA). The 16S rRNA sequences were trimmed and assembled
using Genious 10.2.3 (NJ, US). A continuous stretch of 1440 bp of the 16S rRNA gene of
strain SG772T was obtained and searched against EzTaxon- e-server (3) for identification.
This comparison showed that the closest neighbor for strain SG772T is B. stercoris GAM61 sharing only 94.46% sequence similarity (Figure 2).

Genome sequencing and comparison
The genomic DNA was isolated using E.Z.N.A DNA isolation kit (Omega, Biotek)
following manufacture’s protocol. The sequencing was performed using llumina MiSeq
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Figure 3: Average Nucleotide Identity (ANI) comparison of Blautia brookingsii
strain SG772T sp. nov., with other closely related species with standing
nomenclature. Heatmap was generated with OrthoANI values calculated using the OAT
software.
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(Illumina Inc, CA), 2×250 paired end chemistry. The reads were assembled using SPAdes
3.9.0 (4) and the contigs were validated using Quast (5).

Assembly of the strain SG772T genome produced 52 contigs with the genome size of
3,411,519 bps (N50 = 156,020) and 44.07% GC content. The largest contig was 401,555
bps while the smallest was of 610 bps. The genome contains 57 tRNA genes, 1 rRNA gene
and 3061 coding sequences. Additionally, for SG772T genome, the open reading frames
(ORF) were predicted using Prodigal 2.6 (6) in Prokka software package (7). Transfer RNA
genes were predicted using Aragorn 1.2 (8) and rRNA genes were annotated using Barrnap
0.7 (https://github.com/tseemann/barrnap). The comparison of SG772T genome with its
close species revealed several differences in genome size, G+C content and RNA copies.
The closely related species of the strain SG772T for which the genomes were available
NCBI were obtained and the degree of similarity was estimated using OrthoANI software
(9). For the closest neighbors (Fig 2), OrthoANI values ranged from 69.13 to 73.15%. The
type strain SG772T was observed to be close to Blautia wexlerae DSM19850 with 73.15%
genomic identity while B. schinkii DSM10518 was the farthest (Figure. 3).

Conclusion

As the sequence identity of the phylogenetically closest validated species is < 98.7 %: the
threshold recommended to define a species as per nomenclature (10), we propose the strain
SG772T as a new species Blautia brookingsii sp.nov. strain SG772T (broo.king.sii, L.,
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neut., adj., brookingsii, based on the acronym of the Brookings city where the type strain
was first isolated). The 16S rRNA gene sequence of SG772T is deposited in GenBank under
accession number MH127966.1. Whole genome sequences are deposited in GenBank
under BioProject PRJNA436995. Strain SG772T was deposited in the DSMZ-German
Collection of Microorganisms and Cell Cultures GmbH under DSM 107275 and Culture
Collection of Switzerland (CCOS) under CCOS 1888.
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Table
Table 1: Physiological and substrate utilization characteristics of strain SG772T
compared with its phylogenetic neighbors.
(Refer to Ghimire et al., 2020. Genome sequence and description of Blautia brookingsii
SG772 sp. nov., a novel bacterial species isolated from human faeces, New Microbes New
Infections, Vol 34, 100648 DOI: https://doi.org/10.1016/j.nmni.2019.100648)
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Abstract

Diet is one of the prominent determinants of gut microbiota composition significantly
impacting human health. Recent studies with dietary supplements such as rice bran and
quercetin have been shown to provide a beneficial impact on the host by positively
influencing the gut microbiota. However, the specific bacterial species impacted when rice
bran or quercetin is present in the diet is not well understood. Therefore, in this study, we
used a minibioreactor array system as a model to determine the effect of quercetin and rice
bran individually, as well as in combination, on gut microbiota without the confounding
host factors. We found that rice bran exerts higher shift in gut microbiome composition
when compared to quercetin. At the species level, Acidaminococcus intestini was the only
significantly enriched taxa when quercetin was supplemented, while 15 species were
enriched in rice bran supplementation and 13 were enriched when quercetin and rice bran
were supplemented in combination. When comparing the short chain fatty acid production,
quercetin supplementation significantly enriched isobutyrate production while propionate
dominated the quercetin and rice bran combined group. Higher levels of propionate were
highly correlated to the lower abundance of the potentially pathogenic Enterobacteriaceae
family. These findings suggest that the combination of rice bran and quercetin serve to
enrich beneficial bacteria and reduce potential opportunistic pathogens. However, further
in vivo studies are necessary to determine the synergistic effect of rice bran and quercetin
on host health and immunity.
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Importance

Rice bran and quercetin are dietary components that shape host health by interacting with
the gut microbiome. Both these substrates have been reported to provide nutritional and
immunological benefits individually. However, considering the complexity of the human
diet, it is useful to determine how the combination of food ingredients such as rice bran
and quercetin influences the human gut microbiota. Our study provides insights into how
these ingredients influence microbiome composition alone and in combination in vitro.
This will allow us to identify which species in the gut microbiome are responsible for
biotransformation of these dietary ingredients. Such information is helpful for the
development of synbiotics to improve gut health and immunity.
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Introduction
Gut microbiome influences health and disease (1-3) and is highly affected by diet (4-6).
Some dietary components are known to enhance host health by promoting the growth of
beneficial bacteria in the gut, termed as “prebiotics” (7, 8). Quercetin and rice bran have
been used as prebiotics in mice and pig experiments, showing significant improvements to
the gut microbiota (9-11). Rice bran, a byproduct of the rice milling process, is available,
affordable, sustainable, and a globally produced source of prebiotics. It is known to
supplement nutrients (12), increase beneficial bacteria growth, enhance gut mucosal
immunity (10), and prevent diseases (9, 13-15). Similarly, quercetin (3,3′,4′,5,7pentahydroxyflavone) represents an important subgroup of flavonoids found in fruits and
leafy vegetables (16). Quercetin has received substantial attention in the past few years
from the scientific community for exerting anti-inflammatory effects (17, 18) and its
potential health-promoting properties in the treatment or prevention of cardiovascular
diseases (19), lung and colorectal cancers (20, 21), and colitis (11, 22). Furthermore, the
mammalian body can endure high levels of quercetin without any significant adverse health
effects (23).
Despite multiple studies corroborating the beneficial effect of quercetin and rice bran on
the host, their effect on microbiota varies significantly from study to study and has lower
taxonomic resolution (22, 24-26). Inter-individual variation in in vivo studies are often due
to multiple host-related factors which makes it difficult to interpret microbiome results
(27). In contrast, studying the effect of dietary ingredients on the microbiome in the
absence of confounding host factors can help to better understand the complex microbial
interactions. Bioreactors have been used as model systems to study how dietary ingredients
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shape microbiomes (28). The use of bioreactors allows precise control of the environmental
conditions that affect microbiome composition which provide increased reproducibility
and reveal microbial interactions in a more defined way. Minibioreactor array is an in vitro
anaerobic model system that simulates hindgut conditions for growth of complex, stable
microbiota without interference of host factors (29). Furthermore, this system helps to
identify microbial biotransformations and allows for measuring metabolites produced (30).
We used minibioreactor array systems to gain deeper understanding of how the microbiota
responds to quercetin and/or rice bran without host interference, and hypothesized that the
combination of quercetin and rice bran will have a synergistic positive effect on the gut
microbiota and microbiota metabolism. We observed that the quercetin and rice bran
combination

in

the

minibioreactors

were

effective

to

significantly

reduce

Enterobacteriaceae family members and resulted in higher propionate production. This
study provides novel insights to species-level shifts in the human gut microbiome in the
presence of quercetin and/or rice bran supplementation through an in vitro model.
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Materials and Methods

Donor samples, mini-bioreactor array preparation and sample collection: We obtained
fresh fecal samples from six healthy donors with no prior history of antibiotic consumption
in the past year. The pooled fecal sample from six individuals was used as the inoculum as
our prior study showed that pooled sample represented the individual microbial
composition (31).

The modified BHI medium (31) was used as a control medium. Heat-stabilized rice bran
(RBT 300) was purchased from Rice Bran Technologies (Sacramento, CA, USA), and the
extract was prepared as described previously (14) and then added to the control medium
(final concentration: 2 mg/mL): designated as RB. Quercetin was added to the media at a
final concentration of 75 mg/L and is referred to as QC. The final experimental group
consisted of modified BHI medium with the additions of quercetin (75 mg/L) and rice bran
extract (2 mg/mL) and is identified as QC+RB. Mini-bioreactors (MBRAs) were sterilized,
assembled and the experiment was performed as described previously (32) with minor
modifications. Briefly, the input and output on Watson Marlow pumps were set at 1 rpm
and 2 rpm respectively. The rotating magnetic stirrer was set at 130 rpm. The media
(Control, QC, RB, and QC+RB) (Figure 1A) were allowed to flow continuously for 24
hours each in triplicate. Three hundred microliters of the inoculum was introduced into all
wells with a retention time of 16 hours. The continuous flow model was operated up to 21
days post-inoculation (Figure 1B). Five hundred microliters of the media was collected for
sequencing at day 0 (inoculum), days 4, 7, 14 and 21 and directly frozen to -80oC. Also,
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Figure 1: Overview of the study design: A) A schematic diagram shown the design of
four different media conditions used in this study. Single substrates (quercetin or rice bran)
or the mixture of quercetin and rice bran were used at the final concentration of 75 mg/L
and 2 mg/mL as shown above in the base medium BHI (see Methods section). Final pH of
the media was adjusted to 6.8±0.2 for all conditions. Each condition was run in triplicate
and were inoculated with the same fecal inoculum (see Methods section). B) Outline of the
bioreactor experiment showing time points for fecal inoculation and sample collection for
SCFAs and microbial community analysis.
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samples for short chain fatty acid (SCFAs) determination were collected at days 4, 7, 14
and 21 post-inoculation with dietary treatments and controls (Figure 1B).

Microbial DNA extraction and sequencing: DNA isolation was performed on 50 samples
including duplicate inoculum samples. The DNA was extracted from 500 µl of the sample
using a Powersoil DNA isolation kit (MoBio Laboratories Inc, CA) following the
manufacturer’s instructions. After extraction, the quality of DNA was measured using
NanoDropTM one (Thermo Fisher Scientific, DE) and quantified using Qubit Fluorometer
3.0 (Invitrogen, CA). The DNA samples were stored at -20oC until further use. To analyze
the variation of the microbial composition over time, all samples were amplicon sequenced
using an Illumina MiSeq platform with paired-end V3 chemistry. The library was prepared
using an Illumina Nextera XT library preparation kit (Illumina Inc, CA) targeting V3-V4
regions of the 16S rRNA. The libraries were bead normalized and multiplexed before
loading into the sequencer. We also performed shotgun metagenome sequencing on twelve
samples obtained from day 21 to identify species level taxonomical differences between
the experimental groups. We used the Nextera XT kit (Illumina, San Diego, CA) for the
preparation of the shotgun metagenome sequencing library. The library was then
sequenced using paired end 300 base sequencing chemistry using a MiSeq platform.

Data analysis: The time-series changes in the microbial communities were analyzed using
16S rRNA community analysis in Quantitative Insights into Microbial Ecology framework
(QIIME, Version 2.0) (33). Briefly, the demultiplexed reads obtained were quality filtered
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using q2-demux plugin and denoised applying DADA2 (34). All amplicon sequence
variants were aligned with mafft (35) to construct a phylogeny with fasttree2 (36). The
outputs rooted-tree.qza, table.qza, taxonomy.qza were then imported into R (37) for
analysis using phyloseq (38). Shannon diversity and bray curtis dissimilarity indices were
calculated as alpha and beta diversity metrices. Kruskal-Wallis test at p=0.05 was
performed to compare the species richness between the groups. The reads were normalized
by rarefying to 30,000 and the taxonomy was assigned to amplicon sequence variants using
the q2-feature-classifier (39) using Greengenes as the reference (40). Rarefying the reads
to 30,000 were enough to estimate total diversity and taxonomy (Supplementary Figure
1A). Initially, a total of 947 amplicon variants were identified from 50 samples. The
average number of non-chimeric reads per sample obtained in Qiime2 pipeline was
92,512±27,631 (mean ± SD). The amplicon sequence variants obtained were filtered to
select those which are present in at least 20% of samples with a count of 10 each or
amplicon sequence variants with > 0.001% of total median count reducing the total number
to 581.

For shotgun metagenomes, raw fastq sequences were quality controlled using Fastqc
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/)

and

host

reads

were

removed using metaWRAP pipeline (41). Filtered reads were analyzed for taxonomy using
Kaiju (42) against the proGenomes database (43) using default parameters. The percentage
abundance of each taxon was plotted using Explicit v2.10.5 (44). The samples from day 21
yielded a total of 39,332,649 reads of which 70. 86% were classified to 161 different
species, whereas 185,188 (5.55%) and 9,278,647 (23.59%) reads remained as unclassified
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bacteria or unassigned to non-viral species, respectively. In addition, the raw counts
obtained for each taxon were used for calculation of alpha and beta diversity using the
phyloseq package in R. For identification of differentially abundant taxa in QC, RB and
QC+RB compared to control medium, the raw counts of abundance of each taxon was then
Log10(x+1) transformed and fed to DESEq2 (45) package in R. Bacterial taxa which
significantly altered from the control were further filtered out with the criteria of at least
log2foldchange (Log2FC) of ≥ 2 and padj value > 0.05. The enriched taxa were selectively
analyzed for their co-relation to SCFAs phenotypic data using Spearman correlation
method in R.
Estimation of Short Chain Fatty Acids (SCFAs): For the estimation of SCFAs, 800 µl of
samples were collected from each mini-bioreactor, mixed with 160 µl of 25% mphosphoric acid and frozen at -80°C until further analysis. Later, the frozen samples were
thawed and centrifuged (>15,000 × g) for 20 min. Five hundred microliters of supernatant
was collected in the tubes before loading into the gas chromatography- mass spectrometry
(GC-MS) (Agilent Technologies, USA) for analysis (31). The SCFA concentrations were
compared between the groups using the Kruskal-Wallis test followed by the Dunn test with
Benjamini-Hochberg correction in R and visualized using GraphPad Prism 6.0.
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Results

Rice bran produced larger shift in microbiota composition when compared to
quercetin
The microbial community richness indicated by the Shannon diversity index showed
significant differences in the early days (days 4 and 7) due to addition of rice bran in the
media whether alone or in combination with quercetin (Supplementary Figure 1B). No
significant changes in the richness was observed among the groups on day 14 and day 21,
suggesting the stabilization of the microbial communities by day 14. Also, on day 21,
shotgun metagenome analysis showed no differences in the richness between the four
conditions (Figure 2B). In contrast, marked differences between the communities were
evident as early as day 4 by beta diversity analysis (Supplementary Figure 2A). Rice bran
supplementation showed a greater shift in the bacterial community as shown on days 7, 14
and 21 (Supplementary Figure 2B, 2C, 2D). Based on Bray-Curtis distance, RB and
QC+RB treatments were similar to one another and clustered separately from control and
QC. This supports that there was a limited shift in the community following addition of
quercetin when compared to rice bran (Supplementary Figure 2). Shotgun metagenome
sequencing at day 21 also indicated significant differences in the community profile,
primarily influenced by the addition of rice bran extract in the medium (Figure 2C).

When examined taxonomically, the baseline inoculum composition was dominated by
Prevotellaceae (29.9±0.87%), followed by Ruminococcaceae (18.82±0.81%) and
Lachnospiraceae (12.66±0.4%). Also, Enterobacteriaceae was found to be very low in
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Supplementary Figure 1: Exploratory analysis of predicted taxa and alpha diversity
of microbiota in quercetin and rice bran: control, QC, RB and QC+RB medium and
inoculum obtained using 16S rRNA community analysis A) Rarefaction curves
measuring the bacterial diversity in fecal communities. The curves are based on V3-V4
16S rRNA gene sequences obtained from a total of 48 samples (12 each from control, QC,
RB, and QC+RB) from day 4, 7, 14 and 21 and duplicate inoculums B) Alpha diversity of
four groups (control, QC, RB and QC+RB) at day 4, 7, 14 and 21.
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Supplementary Figure 2: Beta diversity assessment of the microbiota communities
formed at days 4, 7, 14 and 21 among four groups of media condition (Control, QC,
RB and QC+RB) determined using 16S rRNA sequence analysis. The communities
were ordinated using the “MDS” method followed by Bray-Curtis distance calculation to
visualize the difference between the groups. Statistically, PERMANOVA using adonis was
calculated on the beta diversity with p=0.004. The upper panel represents the beta diversity
in early stages (day 4 and day 7) and the lower panel represents in later stages (day 14 and
day 21).
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Figure 2: Gut microbiota compositional changes following quercetin and rice bran
supplementation A) Temporal family-level composition of the most abundant 12 bacterial
taxa at day 4, 7, 14 and 21 and inoculum determined using 16S rRNA community profiling
for Control, QC, RB and QC+RB conditions. B) Alpha diversity measure (Shannon
diversity) between Control, supplemented with QC, supplemented with RB and
supplemented with QC+RB determined using shotgun metagenome sequence analysis at
day 21. Kruskal-Wallis test was performed for the Shannon diversity indices obtained for
the groups (p=0.27). C) Beta diversity among the control, QC, RB and QC+RB groups
were obtained using shotgun metagenome sequence analysis on day 21. “MDS” ordination
followed by Bray-Curtis distance calculation was used to visualize the differences between
the groups (adonis, p= 0.004).
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inoculum (0.33±0.097%). However, the abundance of Prevotellaceae was reduced to ~ 0.0
% after 21 days in all treatment groups suggesting that not all taxa in the inoculum were
supported for growth. Over time, there was a major shift in the composition of the
microbiota between the groups starting as early as day 4 (Figure 2A). The control and
quercetin medium were dominated by Enterobacteriaceae, followed by Lachnospiraceae
at day 4. However, by day 21, Lachnospiraceae dominated the control and QC conditions
followed by Bacteroidaceae. The abundance of Enterobacteriaceae was reduced from
34.16±1.92 % and 33.26±1.11% on day 4 to 17.62±4.2% and 18.53±3.88% in control and
QC medium respectively by day 21 (Figure 2A, 2B). Even though ~50% reduction of
abundance of Enterobacteriaceae was observed for both control and QC medium at day
21 compared to day 4, the population of Enterobacteriaceae tend to stabilize. However,
Enterobacteriaceae were highly reduced in both RB and QC+RB conditions. In RB
medium, Enterobacteriaceae was only reached to 10.212±2.14% at day 4 which further
reduced to 6.33±2.59% by day 21. At day 21, Veillonellaceae and Lachnospiraceae
dominanted the RB medium. Similarly, the dominant family were Lachnospiraceae,
Veillonellaceae and Bacteroidaceae in the quercetin and rice bran combination (QC+RB)
on day 21. Strikingly, on day 21, the abundance of Enterobacteriaceae was reduced by
~18.22% to 4.20±3.16% compared to day 4 on QC+RB condition. At day 21, when mean
abundance of Enterobacteriaceae was compared between control, QC, RB and QC+RB,
significant reduction was observed in RB and QC+RB (Kruskal-Wallis, p=0.0064).

On day 21, we performed shotgun metagenome analysis to identify the species level
differences among the four groups (Figure 3). Based on DeSEQ2 analysis, 53 species were
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significantly altered in QC+RB medium. The combination (QC+RB) enriched 13
additional species and reduced 13 others when the cut off value of Log2FC≥ 2 and padj
value > 0.05 was applied (Supplementary Table 1). Specifically, members of
Enterobacteriaceae, Escherichia sp. TW09308, E. coli, E. albertii, Citrobacter koseri, and
C. youngae were reduced. The Citrobacter species, including C. rodentium, were also
reduced in RB medium; however, Escherichia species were not significantly reduced in
this medium.

Further, 13 species were altered significantly in the quercetin group (Supplementary Figure
3A), and 70 species in the rice bran group compared to control (Supplementary Figure 3B).
With a cut off Log2FC≥ 2 and padj value > 0.05, Acidaminococcus intestine was the only
enriched taxa in media supplemented with quercetin while Coprococcus catus, Dorea
longicatena, Anaerostipes caccae, Eubacterium limosum and Enterococcus faecalis were
highly reduced. Interestingly, the population of Flavonifractor plautii, a flavonoid
metabolizing bacterium (46, 47) was significantly reduced in quercetin supplementation.
Rice bran supplementation alone enriched 15 species, including six different species from
Veillonella (Supplementary Table 1).

Quercetin and rice bran combination yield higher propionate levels and reduces
members of Enterobacteriaceae family
Along with the changes in the taxonomy of the microbial community, diet alters the
metabolic profile of a community (48, 49). To understand how these dietary substrates have
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Figure 3: Impact of quercetin (QC) and rice bran (RB) supplementation on bacterial
taxonomy. Species-wise variation of the most abundant (top 25) of the bacterial taxa
determined by shotgun metagenome sequencing at day 21 (endpoint) for control, QC, RB
and QC+RB conditions in triplicate.
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Figure 4: Impact of quercetin and rice bran (QC+RB) supplementation on bacterial
species that are significantly altered in QC+RB when compared to the control
medium. The differential significance of the species was calculated by using DESEq2 (See
Supplementary Table 1) from shotgun metagenome sequence analysis at day 21. The left
column represents bacterial species-level taxa while the colors indicate their corresponding
phyla (“Blue” =Firmicutes, “Brown” =Bacteroidetes, “Pink” =Proteobacteria, “Orange”
=Actinobacteria, “Green” =Chlamydiae).
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Supplementary Figure 3: Impact of quercetin and rice bran (QC, RB)
supplementation on bacterial species that are significantly altered in A) QC and B)
RB when compared to the control medium. The endpoint (day21) shotgun metagenome
sequence analysis was performed and the differential significance of the species was
calculated by using DESEq2 (See Supplementary Table 1). The left column represents
bacterial species-level taxa while the colors indicate their corresponding phyla (“Blue”
=Firmicutes,

“Brown”

=Bacteroidetes,

=Actinobacteria, “Green” =Chlamydiae).

“Pink”

=Proteobacteria,

“Orange”
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altered the fermentation potential of the microbiota, we measured SCFAs from each
minibioreactor on days 4, 7, 14 and 21. We observed that the amount of each SCFA
produced was stable by day 14 and at the endpoint, with marked differences between the
groups (Figure 5A, 5B, 5C, 5D, 5E). At day 21, communities formed in the control and RB
weighted strongly towards acetate and butyrate production respectively (Supplementary
Figure 4). Statistically at day 21, acetate production in QC+RB group (48.01±3.3 mM) was
significantly different from the RB group (33.33±2.44 mM) (Figure 5F). The butyrate
production in the RB medium was higher but not significantly different compared to the
other groups (Figures 5H). Similarly, the medium supplemented with quercetin and rice
bran (QC+RB) weighted towards the production of propionate and butyrate
(Supplementary Figure 4). Rice bran alone and combined quercetin and rice bran
supplementation significantly raised propionate levels by at least 3 folds compared to the
QC group alone (Figure 5G). In contrast, QC supplementation in the medium, weighted
towards the production of minor SCFAs, i.e. valerate, isovalerate and isobutyrate.
However, only isobutyrate production was significantly higher in QC compared to QC+RB
group (Figure 5I).

SCFAs production by microbiota has been associated with pathogen inhibition to benefit
the host (50). Physiological levels of SCFAs are reported to reduce Enterobacteriaceae
members by pH mediated action (51). Specifically, propionate production by a propionate
producing consortium has been shown to reduce antibiotic induced dysbiosis (52). In this
study, as higher production of propionate weighted towards QC+RB medium at day 21, we
estimated the correlation of abundances of significantly altering members of
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Supplementary Figure 4: Biplot showing ordination of short-chain fatty acid
production and bacterial communities formed at day 21 in control, QC, RB and
QC+RB conditions. Abundances of the bacterial communities at day 21 determined by
shotgun metagenomics were used with SCFAs profiles of day 21 to generate the plot.
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Figure 5: Effect of quercetin (QC) and rice bran (RB) on short Chain Fatty Acids
(SCFAs) production in QC, RB, and QC+RB compared to control medium in
minibioreactors. A-E represent the periodic variation of acetate, propionate, butyrate,
isobutyrate and isovalerate at day 0, 4, 7, 14 and 21 respectively. F-J represent the
comparison of concentrations of acetate, propionate, butyrate, isobutyrate and isovalerate
respectively from control, QC, RB and QC+RB medium at day 21 (endpoint). KruskalWallis test was performed between the groups and posthoc (Dunn test) analysis was
performed to identify the different significant groups. “*” represents significance at 0.05.
Error bars represent standard error of the mean of data obtained from three different
bioreactors.
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Figure 6: Spearman correlation of Enterobacteriaceae family members (Citrobacter
and Escherichia species) log10 abundances at day 21 determined by shotgun
metagenomics sequence analysis to levels of propionate in the medium. A negative
correlation is expressed by negative values of correlation coefficient “rho” (ρ) with
corresponding p-values.
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Enterobacteriaceae to propionate levels. Significant high negative correlations were
observed between the abundance of the members of Enterobacteriaceae family and
propionate with media change (Figure 6). Citrobacter rodentium (ρ= -0.734, p= 0.009), C.
koseri (ρ= -0.769, p=0.0052), C. youngae (ρ= -0.776, p= 0.0046), Escherichia albertii (ρ=
-0.762, p= 0.0058), E. coli (ρ= -0.762, p= 0.00587) and Escherichia sp. TW09308 (ρ= 0.755, p= 0.0065) (Figure 6A, B, C, D, E, F) were greatly reduced in QC+RB medium,
whereas propionate levels were at least 3 fold and 1.5 fold higher compared to QC and
control medium .

Discussion
In vivo studies have shown changes in microbial communities due to quercetin or rice bran
and describe the improvement of colonization resistance and reduction of colon cancer (11,
14, 53). However, these studies are marked by high variations of the microbiota
composition likely due to host factors. Additionally, very little is known about the
combined effect of quercetin and quercetin on gut microbiota. Thus, we focused on
understanding the impact of quercetin and rice bran separately and in combination using a
minibioreactor array model (32). Also, to gain insights into taxonomical composition, we
performed 16S rRNA sequencing over time and shotgun metagenome sequencing at the
endpoint.

Using modified BHI medium, we were able to capture 30.93 % of the total amplicon
sequence variants from the minibioreactors compared to the inoculum. This finding is
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slightly higher than previous results where the MBRA cultivated only 15-25% of the initial
fecal community (29). The reason for the higher number of cultivated bacteria may be due
to the modified BHI medium which has been shown to cultivate a wide range of gut bacteria
(31). On the other hand, the highly dominant Prevotellaceae was lost in all four conditions
in this study suggesting that fermenter adapted communities can lose much of their initial
diversity (54). The alpha diversity indicated that the richness of the communities in
bioreactors stabilized by day 14 (Supplementary Figure 1B). However, the taxonomical
differences were evident as early as day four following inoculation. The changes in the
relative abundances of taxa after day 14 were lower in control and quercetin supplemented
medium whereas rice bran and combined quercetin with rice bran conditions had a more
homogenized microbial composition after day 4 (Figure 2A). This indicates that the time
required for the stabilization of communities may vary with the substrate used in
minibioreactors in contrast to the previously determined timeframe of one week following
fecal inoculation (29). Such changes in the time required for stabilization and diversity
between the groups can be attributed ecologically to the stochastic rearrangement of the
microbial species and their interactions at early stages because of selection pressure by
substrate (55).

Rice bran is a nutrient-dense food with a unique profile and ratio of bioactive
phytochemicals such as gamma oryzanol, tocotrienols, ferulic acid, vitamin B, betasitosterol and many others (12). It has been reported to be effective in preventing
Salmonella typhimurium (9, 14, 56), rotavirus (57, 58) and norovirus (15) infections by
priming intestinal immune cells. However, very few in vivo studies have highlighted its
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effect on gut microbiota and the reports have striking differences. In a clinical trial,
Zambrana et al., (2019) showed significant enrichment of Veillonella, Megasphaera and
Dialister species at the genus level from gut samples of children from either Nicaragua or
Mali at 12 months’ time (24). Another study by Sheflin et al., (2015) showed a significant
increase in the abundance of Methanobrevibacter smithii, Paraprevotella clara,
Ruminococcus flavefaciens, Dialister succinatiphilus, Bifidobacterium sp., Clostridium
glycolicum, Barnesiella intestinihominis, Anaerostipes caccae and Ruminococcus bromii
OTUs after heat stabilized rice bran was fed to people (3 g/day) (25). The differences in
the enriched taxa could be because of the unique inoculum used in this study. However,
both above studies had lower resolution and report enrichment of different taxa which
could be attributed to a different variety of rice bran being used and individualized host
factors (59-61). The compounding hosts’ factors along with variation in age and geography
(62), diet pattern (63), lifestyle (64-66), etc. play a crucial role in determining the gut
microbiota composition, thus masking the actual effect of the substrate alone upon the
diverse community. In contrast, this study supplies species-level resolution eliminating
host interference and shows Veillonella Prevotella, Dialister, Bacteroides and Alistipes
species are significantly enriched while Oscillibacter, Eubacterium and Citrobacter
species are significantly reduced (Supplementary Figure 3B).

Similar to rice bran, previous studies analyzing microbial composition after quercetin
supplementation yielded variable results among different hosts. Enterobacteriaceae and
Fusobacteriaceae were reported to be positively related to quercetin supplementation
whereas Suttrellaceae and Oscillospiraceae were found to be negatively correlated (26).
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However, Lei et al., (2019) reported an increase in abundances of Bifidobacterium,
Bacteroides, Lactobacillus and Clostridium, with a reduction of Fusobacterium and
Enterococcus in mice fed with quercetin (11). With higher resolution and removal of host
factors, our results contrast with both studies and show enrichment of Acidaminococcus
intestini and decreased abundances of E. limosum, E. faecalis, A. caccae, D. longicatena
and C. catus. The domination of Enterobacteriaceae in medium supplemented with
quercetin (Figure 2A, Supplementary Figure 3C) might have resulted in lower enrichment
of the bacterial taxa as Enterobacteriaceae has been reported to affect quercetin
metabolism by directly or indirectly inhibiting quercetin degrading bacteria (26).

When the combined effect of quercetin and rice bran were analyzed, we find that majority
of the microbial shift is due to the supplementation of rice bran (Figure 2, 3, Supplementary
Figure 2). Most of the taxa enriched or decreased in the combination were very similar to
those affected by rice bran supplementation alone. Compared to quercetin and rice bran
supplementation separately, the combination was observed to significantly reduce
members of the Enterobacteriaceae family (Escherichia and Citrobacter sp.)
(Supplementary Table 1, Figure 6). Enterobacteriaceae consists of class of pathogens that
are low in abundance but have potential to grow and dominate during dysbiotic conditions
(67-69). The reduction of Enterobacteriaceae by combined quercetin and rice bran
suggests a possibly beneficial effect on the host.

The reduction of Enterobacteriaceae members was highly correlated with greater
propionate levels in quercetin and rice bran combined medium (Figure 5G, Figure 6).
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Propionate, along with other SCFAs produced by the gut microbiota, has been previously
implicated in regulating the intestinal morphology and functions (70). Interestingly, unlike
butyrate that is used as an energy source for the colonocytes, the health benefits of
propionate are not restricted to the colon. Propionate has been shown to decrease liver
lipogenesis, and hepatic and plasma cholesterol levels in rats. It has also been implicated
in reducing obesity, by stimulating satiety in mice models. Importantly, propionate has also
been demonstrated as a potential anti-inflammatory and anti-cancer agent. The reported
anti-inflammatory abilities of propionate are suggested to occur through the inhibition of
Nuclear Factor-Kappa B and suppression of IL-6 mRNA and other immune-related gene
expression, while its anti-cancer effects are thought to occur through inhibition of Histone
Deacetylases (HDACs) and regulation of the AP-1 pathway (71-73). Therefore, our
observations of increased propionate levels, along with previous reports on the health
benefits of propionate, demonstrates the importance of both flavonoids and fiber in the diet.
This study, for the first time, reports the combined effect of quercetin and rice bran on the
gut microbial composition in the absence of interfering host factors. Here, we report that
the gut microbial composition was altered favorably by quercetin and rice bran to result in
a significant reduction of opportunistic pathogens that could potentially provide additional
health benefits to the host.
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Conclusion
Overall, the combined effect of quercetin and rice bran to shift gut microbiota to reduce
Enterobacteriaceae was correlated with higher levels of propionate production in vitro.
Even though the impact of these dietary ingredients separately is described to be beneficial
to human health, their combined effect was not known. Our results show that a combination
of substrates such as quercetin and rice bran will be beneficial in excluding enteric
pathogens in the gut. However, it is crucial to culture, isolate and characterize the bacteria
enriched in quercetin and rice bran supplemented medium to develop potential synbiotic
formulations for gut health and immunity. Further, in vivo validation of such a combination
would be necessary to understand its implication on the host.

Raw sequence data from 16S rRNA amplicon sequencing and shotgun metagenome
sequencing associated with this study has been deposited in NCBI Sequence Read Archive
under accession number PRJNA606575.
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Abstract
Clostridioides (Clostridium) difficile is a gram-positive, endospore-forming, anaerobic rod
that causes severe gastrointestinal disease resulting in thousands of deaths every year
worldwide. It is the most common cause of hospital acquired diarrhea with a 15-30%
relapsing rate. C. difficile growth is inhibited by the secondary bile acids deoxycholic acid
and lithocholic acid. Clostridium scindens, an intestinal bacterium capable of 7-αdehyroxylation of primary bile acids (i.e., cholic and chenodeoxycholic acids) to secondary
bile acids, has demonstrated promise to treat C. difficile infections. This study compares
genetic diversity among five C. scindens strains and uses batch and continuous flow minibioreactor culture systems to determine the ability of these strains to inhibit the growth of
C. difficile strain R20291. All five strains inhibited C. difficile R20291, with two distinct
mechanisms observed. Two C. scindens strains directly inhibited C. difficile R20291 in the
absence of cholic acid but also inhibited C. difficile R20291 in a dose dependent manner
when cholic acid was included. Three C. scindens strains directly inhibited C. difficile
R20291 but did not further inhibit when cholic acid was added. Filter-sterilized culture
supernatant from each of the five C. scindens strains inhibited growth of C. difficile R20291
when added to the growth media of C. difficile R20291, but inhibition was significantly
reduced when heat treated culture supernatant was used indicating the presence of heatlabile inhibitors in the culture supernatant. Results indicate that C. scindens inhibits C.
difficile in both a bile acid-dependent and independent manner.
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Importance
Clostridium scindens is normally found in the gastrointestinal tracts of humans and
modifies bile acids produced by the host. These modified bile acids are thought to inhibit
the growth of Clotridioides (Clostridium difficile), a potent intestinal pathogen. Here, we
study the genomes of five strains of C. scindens, perform a genome wide analysis for each
strain, and determine if C. scindens inhibits C. difficile. Results indicate that all C. scindens
strains tested inhibit C. difficile growth by production of secretory extracellular alkaloids.
The presence of bile acids enhances C. difficile inhibition by two C. scindens strains.
Substantial differences in the nature and the degree of inhibition of C. scindens against C.
difficile are observed. Such metabolic and genetic variations in capabilities of C. scindens
strains to inhibit C. difficile is an important consideration during C. difficile infection
treatments. Utilizing C. scindens strains to inhibit C. difficile through bile acid-independent
mechanisms could lead to improved bacteriotherapy against C. difficile infection.

Key words: Clostridium scindens, Clostridiodes difficile, bioreactor, dual inhibitory
mechanism
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Introduction
Clostridioides (Clostridium) difficile is a Gram-positive, endospore forming bacterium
producing mild to severe diarrhea leading to pseudomembranous colitis and death (1). In
the United States, C. difficile causes 450,000 infections and 29,000 deaths annually (2). C.
difficile infection can be effectively treated by vancomycin and fidaxomicin (3), however,
use of these and other antibiotics perturb the intestinal microbial community which may
increase the severity of the C. difficile infection (4). Furthermore, following antibiotic
treatment, 15-30% of C. difficile infections relapse into an active infection (3, 5). Fecalmicrobiota transplantation has been recommended as an alternative therapy against such
relapsing infections with ~90% success rate (6-8). Use of fecal microbiota transplantation
is debated among scientists because of the variable bacterial community of the fecal
transplant, difference in the recipient genotype (9), potential for transfer of pathogens (10),
differences in dosage and administration methods. A better understanding of the colonic
microbiota and how fecal microbiota transplantation therapy is effective would be
advantageous. Recently, the microbial metabolism of bile acids has been recognized as
being an important component of C. difficile control in the intestine.

Bile acids are synthesized in the liver from cholesterol and secreted into the proximal small
intestine as a component of bile. The primary bile acids in humans are cholic acid (CA;
3α,7α,12α-trihydroxy-5β-cholanic acid) and chenodeoxycholic acid (CDCA; 3α,7αdihydroxy-5β-cholanic acid) each of which are conjugated to glycine or taurine in the liver
at the 3 position. While in the small intestine, bile acids aid in the absorption of lipids and
lipid soluble vitamins with approximately 95% reabsorbed by the distal small intestine and
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returned to the liver via enterohepatic circulation. Approximately 5% of bile acids escape
reabsorption and enter the colon and are exposed to the colonic microflora (11). Many
colonic bacterial species are known to deconjugate both the glycine and taurine moieties
resulting in free CA and CDCA (12). These free bile acids, in turn, undergo a variety of
oxidation-reduction reactions but the most quantitatively important and irreversible
reaction is 7α-dehydroxylation of primary bile acids to secondary bile acids (11). This
reaction generates (DCA; 3α,12α-dihydroxy-5β-cholanic acid) from CA and lithocholic
acid (LCA; 3α-hydroxy-5β-cholanic acid) from CDCA.

Both primary and secondary bile acids are reported to affect C. difficile germination and
outgrowth. Microscopic examination indicates taurocholic acid (TCA), CA, and DCA
facilitate germination of C. difficile endospores. CA (12 mM) and DCA (1.9 mM) each
inhibit growth of C. difficile vegetative cells, but CA at 1.2 mM does not affect cell growth
on agar plates (13, 14). These observations have led to improved endospore recovery and
germination on selective agar plates for clinical testing (13).

Secondary bile acids have been reported to inhibit C. difficile. Studer et al. (15)
demonstrated that a combination of 12 murine intestinal isolates, when given to germ free
mice, are not protective against a C. difficile challenge but addition of C. scindens, an
intestinal species known to 7α-dehydroxylate bile acids (16), to the microbial mix was
protective during the early stages of infection. Using a comprehensive analysis of murine
and human intestinal microbiota, Buffie et al. (17) correlated C. scindens with inhibition
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of C. difficile growth. Additionally, these workers used an in vivo murine model to show
C. scindens was protective against a C. difficile infection and DCA was also correlated
with C. scindens and inhibition of C. difficile. In contrast to the bile acid theory, Kang et
al. (18) observed that C. difficile inhibited C. scindens growth in culture by secretion of
proline-base cyclic peptide antimicrobials and, surprisingly, that at least two strains of bile
acid 7α-dehydroxylating bacteria, C. scindens ATCC 35704 and C. sordellii ATCC 9714,
secrete tryptophan-derived antimicrobial peptides which inhibit C. difficile. Although, C.
scindens associated production of DCA in the colon has been shown to provide protection
against C. difficile (15, 17), high accumulation of DCA is toxic to colonocytes (19).
Colonocytes undergo major changes in their DNA and metabolism properties that affects
cell division to produce colon cancer (20-25). High levels of DCA can predispose to colon
cancer, the third most common cause of cancer death in the US (26, 27).

This study compares the genomes of 5 strains of C. scindens and tests their ability to inhibit
C. difficile R20291, a hypervirulent ribotype 027 strain, in both batch and continuous
culture. C. scindens ATCC 35704 was originally isolated from feces from a health human
subject and shown to convert 17-hydroxylated corticoids to androstans (C19 corticoids)
and also exhibits bile acid 7α-dehydroxylation (15). C. scindens TH82, C. scindens M18,
C. scindens I10, and C. scindens Y1113 were also isolated from feces from a healthy human
and possess bile acid 7α-dehydroxylation activity (28, 29). All strains exhibit high levels
of bile acid 7α-dehydroxylation activity (30) but otherwise exhibit unique phenotypic or
metabolic characteristics (28, 29). Our results show that among these C. scindens strains,
both bile acid-dependent and bile acid-independent inhibition of C. difficile are present.

108
Materials and Methods
Strains and culture conditions: C. scindens TH82, C. scindens M18, C. scindens Y1113,
C. scindens I10 were originally obtained from the P.B. Hylemon (Virgina Commonwealth
University, Richmond, VA USA).

C. scindens ATCC 35704 was purchased from

American Type Culture Collection (Manassas, VA, USA). C. difficile R20291 was
obtained from the laboratory Dr. Trevor Lawley (Sanger Institute, UK). Brain Heart
Infusion broth modified (BHIM) was prepared as indicated: 37 g/L brain heart extract,
5.0g/L yeast extract, 10.0g/L pectin, 10.0g/L inulin , 0.3 g/L L-cysteine, 0.25 mg/L
resazurin, and 1.0 mg/L menadione was added to 900 ml water, pre-reduced and sterilized
by autoclaving at 121oC and 15 psi for 30 min. Following autoclaving, 100 ml of filter
sterilized 4-morpholinoethanesulfonic acid hydrate (1 M, MES hydrate) was added as the
buffering agent and pH was adjusted to 6.8 using 10 M sodium hydroxide. Finally, 1.7ml
of acetate (30 mM), 2ml of propionate (8 mM), 2ml butyrate (4mM), 100µl isovalerate
(1mM), 1ml hemin (0.5 mg/ml), 10 ml of ATCC vitamin and ATCC mineral mixtures
respectively were added per liter of media. All cultures were manipulated using an
anaerobic chamber (Coy Lab Products, Grass Lake, MI) containing 5% CO2, 10% H2, and
85% N2 maintained at 37oC.

Genome sequencing assembly, annotation, comparative analysis and secondary
metabolite prediction: To generate high quality genomes, strains were sequenced using
Illumina short read (Illumina Inc, CA) and the Oxford Nanopore MinION long read (SQLLSK108, Oxford Nanopore technologies, UK) sequencing technologies. For Illumina
sequencing, genomic DNA was isolated from 0.5 ml of overnight culture using E.Z.N.A.®
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Bacterial DNA Kit (Omega Biotek, GA). Sequencing library was then prepared using
Nextera XT Kit (Illumina Inc, CA). Libraries were sequenced using 250 base paired end
chemistry on an Illumina MiSeq platform. FASTQ files were generated using Casava
v1.8.2 pipeline (Illumina, Inc, CA).

High molecular weight DNA required for MinION sequencing was extracted following
modified phenol: chloroform method as described previously (41). High molecular weight
DNA was quantified using Qubit dsDNA HS assay kit (Invitrogen, OR) kit and Qubit®
3.0 Flurometer (Thermo Fisher Scientific Inc., MA). For Oxford Nanopore sequencing,
1.5-2.0 µg of high molecular weight DNA was fragmented by centrifugation using G-tube
(Covaris Inc., MA), and the ends were repaired using NEBNext End Repair/dA-Tailing
Module followed by ligation of adapters. MinION long read sequencing was performed
using the 1-directional (1D) sequencing kit according to manufacturer’s protocol (SQLLSK108, Oxford Nanopore technologies, UK).

To compare the genetic makeup of the C. scindens strains, hybrid genomes were generated
using short and long reads. Initially, long reads were assembled using miniasm (42). The
assembled long reads were then used to scaffold assembly of the short reads using
Unicycler v 0.4.0 (43) to produce hybrid assembly. Genomic features were evaluated and
validated from hybrid sequences using Quast (44). Total number of tRNAs were predicted
using ARAGORN (45). Also, the assembled genome sequences were annotated using
Rapid Annotation using Subsystem Technology (46). Amino acid FASTA sequences
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obtained from RAST were used to calculate identities between the sequences using two
way Amino Acid Identity (AAI) calculator with minimum identity of 20% (47). To
determine the diversity and variations of bile acid inducible (bai) genes which are
responsible for bile acid 7α-dehydroxylation, the hybrid genomes of five C. scindens
strains were separately examined for the presence of bai genes using CLC genomics
workbench 9.5.3 (Qiagen Bioinformatics, CA) at 80% identity level. C. scindens VPI
12708 bai operon sequences were used as reference sequences for bai genes comparison
[GenBank: U57489.2]. Additionally, these 5 hybrid assemblies of the C. scindens strains
were annotated using Prokka 1.13 (48). The obtained protein sequences were visualized
using Snapgene Viewer 4.2.6 (GSL Biotech LLC) to locate bai operon. Genes baiA1, baiF,
baiE and baiB were annotated by Prokka and remaining genes were manually located using
blastp in nrNCBI with default parameters. Amino acid sequences of baiA1/3, baiA2, baiB,
baiCD, baiE, baiF, baiG, baiH, baiI and baiJKL were separately aligned employing the
ClustalO 1.2.4 web server. To identify the presence of mcbB gene encoding the production
of 1-acetyl--carboline in C. scindens, know sequence of mcbB gene from other species
was used for sequence search against C. scindens genomes. mcbB gene from C. innocuum
2959 in NCBI database (accession number NZ_KB850948.1) and ten other Streptococcus
species (McbB gene accessions: EFM29959.1, VEI59856.1, VTQ24966.1, CIZ00836.1,
EMP71847.1, RGR60169.1, RKV90253.1, RFU54189.1, AXQ78541.1 and RFU54189.1)
in UniprotKB database were used for homology search using CLC genomics workbench
9.5.3 (Qiagen Bioinformatics, CA) at 30% sequence identity and 50% coverage.
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Batch co-culture of C. scindens strains with C. difficile: To analyze the effect of genetic
differences in phenotypic expression related to resistance against C. difficile, in vitro batch
co-culture was performed. C. scindens strains and C. difficile R20291 were maintained
inside anaerobic chamber in BHIM medium. To examine the effect of bile acids on C.
difficile inhibition by C. scindens, strains were co-cultured in various concentrations of CA
and DCA.

Concentrations were similar to health human bile acid fecal water

concentrations (49). Cultures were grown overnight in BHIM and OD600 was adjusted to
0.5 using BHIM. Each C. scindens strain was inoculated with C. difficile in the ratio 9:1
(vol/vol) in 1 ml of BHIM in triplicate. The mixture was incubated at 370C for 24 hours
anaerobically then serially diluted and spread on C. difficile selective agar to enumerate the
C. difficile as described before (SQL-LSK108, Oxford Nanopore technologies, UK).

Co-culture of C. scindens strains with C. difficile in continuous flow mini-bioreactors:
C. scindens strains were co-cultured in BHIM with C. difficile in continuous flow model
using minibioreactors arrays (MBRAs) as described previously with 8 hour retention time
(50). Similar to batch co-culture assays, C. scindens and C. difficile were mixed at a 9:1
(vol/vol) ratio in duplicate. Co-culture of C. scindens and C. difficile were incubated CA
(50 µg/ml; 116 μM) and BHIM with DCA (50 µg/ml; 121 μM). Samples were collected
prior inoculation and 1, 2- and 3-days post inoculation. Samples were enumerated for C.
difficile. For short chain fatty acid analysis, eight hundred microliters of the bacterial
sample from MBRAs were added to 160 µl of freshly prepared 25% (w/v) m-phosphoric
acid and frozen at -800C. For analysis, samples were thawed and centrifuged (>20,000×g)
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for 30 min and 600 µl supernatant was subjected to gas chromatography (Agilent
Technologies, USA).

Testing for the production of antimicrobials from C. scindens against C. difficile
R20291: C. scindens strains were grown for 48 hours in BHIM medium then centrifuged
at 10,000 g for 5 min. The supernatant was filtered using a 0.22 µm filter and moved into
the anaerobic chamber and diluted in ratio 1:1 with the 1X BHIM medium. pH was
adjusted to 6.8. An overnight culture of C. difficile R20291 was adjusted to OD600 = 0.5.
Twenty microliters of OD600 adjusted suspension was added to 1 ml of the 1:1 diluted cell
free supernatant (heat treated and untreated) and incubated for 24 hours in triplicate. C.
difficile R20291 was grown in 50% BHIM diluted with anaerobic PBS as a positive control.
After 24 hours, the cultures were serial diluted with anaerobic PBS and plated on
Clostridium difficile selective agar and incubated anaerobically for 24 hours for
enumeration. To access the activity of 1- acetyl--carboline against C. difficile R20291,
we grew the C. difficile in BHIM supplemented with 25 μg/mL of commercially available
1-acetyl--carboline (Aobious Inc, MA) under both heat-treated (650C for 20 minutes) and
untreated conditions in triplicate. OD630 was measured at 0, 24 and 48 hours and analyzed
to obtain inhibition of C. difficile which was expressed as percentage inhibition compared
to the control.

Statistical analysis: Oneway ANOVA was performed in Graphpad Prism v6.0.1.
Dunnett test was used to compare mean values of treatments with control (α = 0.05).
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Results
Genomic analysis of C. scindens strains: To gain insights into the genomic diversity that
might impact the C. difficile inhibition capacity of C. scindens, genomes of five strains
known to exhibit bile acid 7α-dehydroxylation activity, were sequenced. Each genome was
sequenced using Oxford Nanopore long read and Illumina short read platforms. Hybrid
genome assembly produced complete genomes for C. scindens I10, C. scindens M18, while
near complete genomes were produced for C. scindens ATCC 35704, C. scindens TH82
and C. scindens Y1113.

(Table 1). The bai genes, responsible for bile acid 7α-

dehydroxylation, were distributed in two different chromosomal regions of the C. scindens
genomes, the first being a larger complete bai operon consisting of baiB, baiCD, baiE,
baiA2, baiF, baiG, baiH and baiI, while second operon consisted of baiA1/3, baiJ, baiK
and baiL. Both larger and smaller operons were present in C. scindens M18 and C. scindens
Y1113 while only baiA1/3 was present for C. scindens ATCC 35704, C. scindens I10 and
C. scindens TH82 (Figure 1A). The baiJKL operon was not present in C. scindens ATCC
35704, C. scindens I10 or C. scindens TH82. In addition, a second copy of baiA2 was
present in C. scindens ATCC 35704, C. scindens TH82 and C. scindens Y1113 but absent
in C. scindens M18 and C. scindens I10. The baiA1/3 and baiJKL operons were separated
in C. scindens M18 and C. scindens Y1113 by two genes, crtK-2-TspO (tryptophan rich
sensory protein) and hcaR (LysR family transcriptional regulator) (Figure 1B). Unlike C.
scindens VPI 12708, C. scindens M18 and C. scindens Y1113 do not possess a LysR type
transcription regulator between the baiJKL operon and the baiA1 gene. Furthermore, as
upstream and downstream genes could potentially regulate gene expression, we checked
for differences in upstream and downstream genes in both operons. Among the 5 strains,
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Figure 1. Genomic differences among the Clostridium scindens (CS) strains. A) Average
amino acid identity of CS strains. Average amino acid identity (AAI) matrix was obtained
using amino acid identity calculator and visualized using MeV 4.9.0. B) Presence of bile
acid inducible (bai) genes in bai operon in different Clostridium scindens (CS) strains.
Clostridium scindens VPI 12708 bai genes were used for comparison and % identity of
each gene was represented as a heat map. C) Two groups of Clostridium scindens were
formed based on the presence of baiJKL genes. The presence of baiJKL and hcaR genes
in Clostridium scindens -M18 and Clostridium scindens Y1113 are shown compared to
Clostridium scindens ATCC 35704, CS-I10 and CS-TH82. Two separate rows of genes
represent separate chromosomal regions in each individual genome.
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no differences in the large operon were observed up to 8 upstream and downstream genes.
For the second operon, genes in upstream of the baiA1 differed from -5 position whereas
an additional hypothetical protein (winged helix DNA binding domain protein) was
detected in downstream 6th position for only C. scindens M18 and C. scindens Y1113.

Doerner et al. (30) has demonstrated the differences in the dehydroxylation of CA to DCA.
Among these five strains, C. scindens Y1113 was observed to be the highest
dehydroxylating bacteria followed by C. scindens I10, C. scindens M18, C. scindens ATCC
34704 and C. scindens TH82. Such differences could be attributed to the presence of the
bai genes in the bai operons. Even though all strains exhibited the presence of larger operon
baiBCDEA2FGHI in this study, the difference was observed for baiJKL which might
contribute to the differences in bile acid conversion. On other hand, the baiA1/3 was also
present in all the strains but variation in the amino acid composition was observed. The
baiA1/3 gene of C. scindens ATCC 35704, C. scindens I10 and C. scindens TH82 was
determined to have 9 amino acid differences compared to C. scindens M18 and C. scindens
Y1113 (Supp. Figure 1). The differences were in positions 25, 99, 111,118, 133, 204, 209,
210 and 235. Position 111 represented a change in histidine (H), present in C. scindens
ATCC 35704, C. scindens I10 and C. scindens TH82, to asparagine (N) in C. scindens M18
and C. scindens Y1113. At position 111, the positively charged side chain of histidine,
present in C. scindens ATCC 35704, C. scindens I10 and C. scindens TH82, was altered to
a polar uncharged side chain of asparagine in C. scindens M18 and C. scindens Y1113.
Similarly, at position 118, isoleucine, present in C. scindens ATCC 35704, C. scindens I10

116
CS-ATCC
60
CS-I10
60
CS-TH82
60
CS-M18
60
CS-Y1113
60

MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
MKLVQDKITIITGGTRGIGFAAAKLFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
MKLVQDKITIITGGTRGIGFAAAKLFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
************************:***********************************

CS-CSATCC
120
CS-I10
120
CS-TH82
120
CS-M18
120
CS-Y1113
120

GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNSVFSRVSEEDFKNIMDINVNGV
GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNSVFSRVSEEDFKNIMDINVNGV
**************************************:***********:****** **

CS-ATCC
180
CS-I10
180
CS-TH82
180
CS-M18
180
CS-Y1113
180

FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
FNGAWSAYQCMKDAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
FNGAWSAYQCMKDAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
************:***********************************************

CS-ATCC
240
CS-I10
240
CS-TH82
240
CS-M18
240
CS-Y1113
240

RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
RVVGVAPGVVDTDMTKGLPPEILEDYLKTLPMKRMLKPEEIANVYLFLASDLASGITATT
RVVGVAPGVVDTDMTKGLPPEILEDYLKTLPMKRMLKPEEIANVYLFLASDLASGITATT
***********************:****::***********************.******

CS-ATCC
CS-I10
CS-TH82
CS-M18
CS-Y1113

ISVDGAYRP*
ISVDGAYRP*
ISVDGAYRP*
ISVDGAYRP*
ISVDGAYRP*

249
249
249
249
249

Supplementary Figure 1: Sequence alignment of amino acids of baiA1 gene for five C.
scindens strains using ClustalO. The red fonts show the amino acids and their positions
variation.
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Table 1. Genomic features of Clostridium scindens strains compared in this study.

Features
Total contigs
Largest contig (bp)
Total length (bp)
GC (%)
N50
L50
Orthologous protein clusters
Coding sequence
RNAs
tRNAs

ATCC
35704
I10
3
1
3,536,561 3,435,579
3,635,563 3,435,579
46.23
46.36
3,536,561 3,435,579
1
1
3179
3165
3822
3548
65
64
58
57

M18
1
4,020,163
4,020,163
47.38
4,020,163
1
3690
3819
64
56

TH82
141
298,262
3,321,200
46.66
61,248
16
3077
3372
52
51

Y1113
10
1,165,028
3,937,901
47.42
897,417
2
3667
3721
60
55
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and C. scindens TH82, was substantially different than the hydrophobic side chain of
asparagine present in C. scindens M18 and C. scindens Y1113 (Supp. Figure 1).

Kang et al. (18) recently reported that C. scindens ATCC 35704 produce 1-acetyl-carboline, which has an inhibitory effect against C. difficile. However, this study did not
identify the gene responsible for the production of 1-acetyl--carboline in C. scindens. In
other organisms, mcbB

mediates the Pictet Spengler reaction of L-tryptophan and

oxaloacetaldehyde to produce carbolines (31). To determine whether the mcbB homolog is
present in C. scindens, we searched the genomes of all strains sequenced in this study using
all known mcbB sequences from C. innocuum and Streptococcus species. This search did
not find any mcbB homolog in C. scindens when 30% sequence identity and 50% coverage
was used as search cut off.

Phenotypic analysis of C. scindens strains: All five C. scindens strains were tested for
inhibition of growth of C. difficile R20291 using batch co-cultures with varying
concentrations of bile acids (Figure 2). When grown in the absence of bile acid, all C.
scindens strains significantly reduced growth of C. difficile R20291. Reduction of growth
ranged from 8.3±0.02 log10 CFU of C. difficile R20291 grown in monoculture (control) to
7.8±0.08 log10 when grown with C. scindens TH82 or 5.8±0.06 log10 when grown with C.
scindens M18. Additionally, when co-cultured with C. scindens TH82 or C. scindens
Y1113, CFUs of C. difficile R20291 were reduced in a dose-dependent manner when
concentrations of 12.5 – 50 μg/ml of CA were included in the medium. Addition of CA did
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Figure 2. Growth of Clostridioides (Clostridium) difficile (CD) when tested using batch
co-culture with Clostridium scindens (CS) strains in the presence and absence of cholic
acid (CA) and deoxycholic acid (DCA). Clostridium difficile monoculture and all CS
cocultures in the presence of DCA are shown in red; ‘a’ indicates statistical significance
(p<0.05) when compared to the corresponding control culture without DCA. C. difficile in
monoculture, with and without CA, is indicated by ‘b’; no significant difference of C.
difficile CFUs were observed. ‘****’ represents statistical significance at p < 0.001.
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Figure 3. Levels of C. difficile R20291 when cocultured in continuous flow minibioreactor
with C. scindens (CS) strains in the presence of cholic acid (CA) and deoxycholic acid
(DCA). C. difficile was determined by counting colony forming units (CFU) every 24 h for
3 days. A) BHIM medium. B) BHIM containing 50 µg/ml of CA. C) BHIM medium
containing 50 µg/ml of DCA. Statistical analysis was performed by comparing C. difficile
CFUs in pure culture to C. difficile CFUs in coculture. Error bars represent standard error
of mean of two experiment performed in duplicate. One way ANOVA and tukey test was
performed at the 3rd day between the groups where ‘*’, ‘**’, ‘***’, and ‘****’ represent
statistical significance at p = 0.05, p = 0.01, p = 0.001 and p < 0.001 respectively.
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not increase the growth inhibition of C. difficile R20291 by C. scindens M18, C. scindens
ATCC 35704 or C. scindens I10. Addition of DCA (50 μg/ml) reduced the growth of C.
difficile R20291 from 8.2±0.02 log10 to 5.98 ±0.06 log10. None of the C. scindens tested
further reduced growth of C. difficile R20291 cultured in the presence of DCA when
compared to C. difficile R20291 grown in monoculture in the presence of DCA (Figure 2).

C. scindens M18, C. scindens ATCC 35704, C. scindens Y1113, C. scindens TH82 and C.
scindens I10 were also tested for inhibition of C. difficile R20291 grown in continuous
flow culture using a mini-bioreactor array. Similar to batch co-culture, all 5 C. scindens
strain inhibited C. difficile R20291 (Figure 3A) with statistical significance (p<0.05). C.
scindens ATCC 35704 and C. scindens I10 were the most inhibitory, each decreasing C.
difficile R20291 growth by 2.3 log10. Addition of CA (50 μg/ml) substantially increased C.
difficile R20291 inhibition by C. scindens TH82 and C. scindens Y1113 but did not affect
the inhibition of the other three C. scindens strains (Figure 3B). DCA (50 μg/ml)
effectively inhibited growth of C. difficile R20291 in continuous culture reducing control
levels of 8.5±0.01 log10 CFU to 6.0 ±0.04 log10 CFU. Furthermore, addition of C. scindens
strains to C. difficile R20291 cultured in DCA did not significantly reduce C. difficile
R20291 levels with the exception of C. scindens M18 which reduced growth from 6.0
±0.04 log10 to 5.8±0.04 log10 (Figure 3C).

Steady-state production of the short chain fatty acids, acetate, propionate, and butyrate was
determined in continuous culture of the five C. scindens strains with C. difficile R20291
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Figure 4. Concentrations of short chain fatty acids (SCFAs) obtained from coculture of C.
scindens (CS) strains with C. difficile R20291 in continuous flow minibioreactor in BHIM
medium with cholic acid (CA, 50 µg/ml) and deoxycholic acid (DCA, 50 µg/ml) in
duplicate in two experiments. A, B and C represent concentrations of acetate, propionate
and butyrate on day 3, respectively. Statistical comparison using Oneway ANOVA. ‘*’
represents statistical significance at p=0.05.
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(Figure 4). Significant differences were not observed when CA or DCA was added to the
culture medium for most strains. Acetate values ranged from 28 to 45 mM. Values ranged
from 0.7 to 5.4 mM for propionate and 1.2 to 9.5 mM for butyrate. However, the C.
scindens M18 and C. difficile R20291 coculture provided two notable expectations. First,
this coculture displayed a significant increase in acetate from 33.2 to 44.4 mM upon the
addition of CA and, second, displayed a reduction of butyrate from 4.8 mM (control) to 1.2
and 1.7 mM with addition CA and DCA, respectively. Also, cocultures of C. scindens
TH82 and C. difficile R20291 indicated a decrease of butyrate production of 7.4 mM
(control) to 2.4 mM with addition of CA but addition of DCA did not significantly inhibit.

Each C. scindens strain was tested for extracellular material which could inhibit growth of
C. difficile R20291 (Figure 5A). Culture supernatant was collected from each strain and
diluted 1X with fresh medium then used as growth medium for C. difficile R20291. Data
indicate that each strain was inhibitory; C. scindens ATCC 35704 was the most inhibitory
and reduced C. difficile R20291 growth from 7.7±0.2 log10 to 6.9±0.04 log10 while C.
scindens TH82 was the least inhibitory and reduced growth to 7.2±0.01 log10. As shown in
Figure 5A, the inhibition was significantly reduced, but not abolished when culture
supernatant was heat treated. To determine whether heat treatment affects the inhibitory
capacity of 1-acetyl--carboline on C. difficile, heat treated and untreated commercially
available 1-acetyl--carboline was tested against C. difficile R20291 in identical
conditions. Data in Figure 5B Shows that heat treatment did not affect the inhibitory
capacity of 1-acetyl--carboline. Taken together, our results indicate that factors other than
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Figure 5. (A) Inhibition of C. difficile R20291 (CD) by the cell free culture supernatant
obtained from C. scindens (CS) strains cultured in BHIM medium. (B) Effect of heating
on the C. difficile R20291 inhibition capacity of 1- acetyl--carboline. One-way ANOVA
was used for statistical analysis and each mean value was compared to CD. “***” and
“****” represents p-values at 0.001 and < 0.0001.

125
1-acetyl--carboline are responsible for the bile acid independent inhibition of C. difficile
R20291 by the C. scindens strains used in this study.

Discussion
Data presented here indicate that all five strains of C. scindens inhibit the growth of C.
difficile R20291 in batch and continuous-flow culture using two different mechanisms of
inhibition. First, C. scindens M18, C. scindens ATCC 35704, and C. scindens I10 all
inhibit C. difficile R20291 in the absence of CA; the presence of CA does not increase
inhibition. C. scindens M18 was most effective at inhibiting C. difficile growth in batch
culture, causing up to 2.4 log10 reduction (270-fold) of C. difficile R20291 growth. In
continuous-flow culture, C. scindens I10 and C. scindens ATCC 35704 were more
effective, inhibiting C. difficile R20291growth approximately 2.3 log10. Thus, the first
mechanism of inhibition by C. scindens is bile acid independent. Second, C. scindens TH82
and C. scindens Y1113 inhibited C. difficile R20291 in the absence of CA but showed a
dose-dependent increase of inhibition with addition of CA in batch culture and a CAdependent increase in inhibition in continuous-flow culture. In total, these results indicate
that C. scindens TH82 and C. scindens Y1113 inhibit C. difficile R20291 by both a bile
acid independent and bile acid dependent mechanisms and C. scindens ATCC 35704, C.
scindens I10, and C. scindens M18 inhibit C. difficile R20291 only by a bile acid
independent mechanism. The bile acid independent mechanism of C. scindens TH82 and
C. scindens Y1113 is less effective at inhibiting C. difficile R20291 than the bile acid
independent mechanisms of the other three strains.
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These two strains, in the absence of CA, were less effective than C. scindens M18, C.
scindens ATCC 35704, or C. scindens I10 but achieved similar inhibitory effects with the
addition of CA or DCA at 50 ug/ml. The inhibitory action is dependent upon the bile acid
CA and likely not due to CA directly, but due to the conversion of CA to DCA which is a
more hydrophobic than CA and acts as detergent to disrupt cellular membranes and inhibit
cell growth.

Kang et al. (18) have proposed a model for both bile acid dependent and bile acid
independent inhibition of C. difficile. These workers isolated three compounds from C.
scindens; turbomycin A and 1,1,1-tris(3-indolyl)-methane from C. scindens ATCC 9714
and 1-acetyl-β-carboline from C. scindens ATCC 35704. Further experiments indicated
that turbomycin A and 1-acetyl-β-carboline effectively inhibited C. difficile ATCC R9689
and the addition of DCA or LCA, but not CA, significantly increased this inhibition. The
authors propose the combination of bacteriostatic compounds produced by bile acid 7αdehydroxylating bacteria coupled with the detergent-like properties of hydrophobic
secondary bile acids effectively inhibit C. difficile in vivo.

Data presented here are generally consistent with this model, but inconsistencies remain.
Kang et al. (18) show that C. scindens ATCC 35704 does not inhibit C. difficile ATCC
R9689, in spite of the fact C. scindens ATCC 35704 is producing 1-acetyl-β-carboline.
Addition of CA to the co-culture also did not inhibit C. difficile ATCC R9689. Addition
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of C. scindens VPI 12708 to the co-culture of C. scindens ATCC 35704 and C. difficile
ATCC R9689 did inhibit the growth of C. difficile ATCC R9689. However, it is unclear
what factors C. scindens VPI 12708 contributed, as control co-culture experiments with C.
scindens VPI 12708 and C. difficile ATCC R9689 were not reported. C. scindens VPI
12708 may have acted alone or perhaps in synergy with C. scindens ATCC 35704. Our
data indicate that a growing C. scindens ATCC 35704 culture or culture supernatant can
effectively inhibit C. difficile which is consistent with this strain producing bacteriostatic
compounds. However, the heat treatment of culture supernatant reduced the inhibitory
effect while heat treated 1-acetyl--carboline did not show any reduction in inhibition.
These data suggest that a protein mediated mechanism is present in addition to 1-acetyl-βcarboline mediated inhibition of C. difficile R20291 by C. scindens ATCC 35704 in our
experiments. Homology based searches using known mcbB genes responsible for the
production of 1-acetyl-β-carboline in other bacterial species did not identify any homologs
in all C. scindens strains used in this study. Clostridial genomes in general exhibit high
sequence variation (32). This high sequence divergence may be the reason why homologybased searches failed to identify 1-acetyl-β-carboline encoding gene in our searches.

In a recent study, freshly isolated, clinical C. difficile strains were administered to
conventional mice then disease severity was measured and correlated to virulence factors
and genomic features (33).

The results indicated that pathogenic C. difficile strains

produce a range of disease severities which are not necessarily correlated with known
virulence factors. For example, C. difficile intestinal burden, toxin production, sporulation
rate, and germination efficiency were not associated with disease severity but displayed
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wide variations across the strains tested. Tolerance to the secondary bile acid lithocholic
acid was correlated with disease severity but also displayed wide variation. The C. difficile
RT027 genotype, which represented 6 of the 21 strains tested, was correlated with the
greatest disease severity and mortality, except for one RT027 strain which was the least
pathogenic of all 21 strains. The workers went on to show that no fewer than nine groups
of genes, other than the previously recognized pathogenicity loci, were found to correlate
with disease severity. Burns et al. (34) have shown that significant variation exists in the
rate of sporulation of C. difficile strains and Heeg et al. (35) have shown that significant
variation exists in germination of C. difficile endospores in response to bile acids and other
factors. These data show that virulence factors and genetic variation among C. difficile
strains is substantial which suggests sensitivity of C. difficile strains toward bacteriostatic
factors may vary. While in general agreement, our data differ from other studies (18) which
could be due to differences between the C. difficile strains employed. This study used C.
difficile R20291, a ‘hypervirulent’ RT027 strain isolated from a recent disease outbreak in
the United Kingdom (36), whereas Kang et al. (18) used the ‘historic’ C. difficile R9689
(37). In batch culture experiments, Kang et al. (18) observed C. difficile R9689 was not
sensitive to C. scindens ATCC 35704 in the presence of CA indicating C. difficile R9689
may not be sensitive to 1-acetyl-β-carboline at the levels produced by C. scindens ATCC
35704. In this study, C. scindens ATCC 35704 effectively inhibited C. difficile R20291
(Figure 2) suggesting C. difficile R20291 is sensitive to the bacteriostatic compound, 1acetyl-β-carboline, at the levels produced by C. scindens ATCC 35704 (18). Our data
suggest C. difficile R20291 has a varied response to CA.

We show that C. difficile

R20291 cultured with C. scindens TH82 or Y1113 display a dose-dependent response to

129
CA however when C. difficile R20291 is cultured with C. scindens ATCC 35704, C.
scindens I10, or C. scindens M18, CA does not have an effect. This suggests that C.
difficile R20291 may be differentially inhibited by CA in the presence various C. scindens
strains possibly due to the bacteriocins produced by the C. scindens strains. In sum, these
observations indicate that phenotypic and genetic variation of C. difficile strains used to
study the inhibitory effects of C. scindens may significantly influence the results.

Conclusion
Hence, the data presented here indicate that C. scindens effectively inhibits C. difficile in
both batch and continuous culture. Growth inhibition of C. difficile by some C. scindens
strains proceed by a bile acid dependent mechanism, as evidenced by the dose dependent
inhibition by CA in the presence of some C. scindens strains. All C. scindens tested also
inhibit C. difficile in a bile acid independent manner, as indicated by the observation
spentC. scindens culture supernatant inhibited C. difficile. Since antibiotic treatment often
causes recurrence of C. difficile infection, identifying resident members of the commensal
gut microbiota that inhibit C. difficile growth and provide colonization resistance has been
proposed as a means of developing defined bacteriotherapy against C. difficile infection.
C. scindens is a member of gut commensal that has shown high effectiveness in inhibiting
C. difficile. However, focusing on using secondary bile acid production of C. scindens
alone as a means of developing bacteriotherapy may have long-term health complications
for patients. For example, high activity bile acid dehydroxylating strains can induce
colorectal cancer by producing DCA in colon which induce colonal stem cells in colonic
epithelium to develop colon cancer (38-40). Therefore, utilizing C. scindens strains which
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inhibit C. difficile through bile-independent mechanisms could be an effective means of
developing defined bacteriotherapy against C. difficile without the long-term risk of colon
cancer causation.
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OVERALL CONCLUSION AND FUTURE DIRECTION

This study examined the Prevotella dominated human gut microbiota utilizing culturomics
and addressed questions regarding individual bacteria colonization resistance against C.
difficile in vitro. According to results from this study, the majority of the Prevotella
dominated gut microbiota confer colonization resistance against C. difficile. However, a
detailed mechanism of resistance against the pathogen by each species needs further
investigation. Additionally, using the combinatorial assembly technique, we found that the
minimum set of bacteria required as a community to provide protection against C. difficile
is twelve. With detailed phenotypic characterization of the individual species in terms of
substrate utilization, short chain fatty acid production, genetic traits and inhibition against
C. difficile presented in this study, it is now possible to undertake the ecological community
assembly, resilience and colonization resistance studies using a Prevotella dominated
microbial community. These studies will help us develop the microbial therapeutics against
multidrug resistance gut pathogens such as C. difficile and understand chronic
inflammatory gut diseases such as Crohn’s disease and inflammatory bowel disease.

The ability to isolate two novel species from a Prevotella dominated microbiota on a single
medium in this culturomics study suggests this microbiota enterotype is not well defined.
Also, the effect of prebiotic substrates such as rice bran and quercetin on this microbiota
includes the potential benefits of reduced Enterobacteriaceae by enhancing propionate
production. However, further culturing and isolation of the microbes enriched in the
combined rice bran and quercetin substrate is warranted due to their potential as synbiotics
that are useful in preventing gut dysfunction.
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The hypothesis that C. difficile is inhibited by bile dependent mechanisms of C. scindens
is supported by this study. However, strain wise variations are apparent when genetically
and phenotypically analyzing for inhibition against C. difficile. Additionally, some strains
of C. scindens were also able to inhibit C. difficile even in the absence of bile. Thus, use of
non-bile converting, but C. difficile inhibiting, C. scindens strains would not only reduce
the negative impact of microbe mediated high deoxycholate production in the gut but also
provide colonization resistance against C. difficile.

With interpersonal variation, the key question of how the gut microbiota assembles and
how it affects colonization resistance against gut pathogens remains poorly understood.
Even though our study provides insights into species that inhibit C. difficile in vitro, further
in vivo studies are required to explore their full potential as a community. This knowledge
will help develop biotherapeutics against gut diseases.

